REVIEW article

Front. Oncol., 12 May 2020

Sec. Cancer Metabolism

Volume 10 - 2020 | https://doi.org/10.3389/fonc.2020.00554

Unresolved Complexity in the Gene Regulatory Network Underlying EMT

  • The Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Science, Queen's University Belfast, Belfast, United Kingdom

Abstract

Epithelial to mesenchymal transition (EMT) is the process whereby a polarized epithelial cell ceases to maintain cell-cell contacts, loses expression of characteristic epithelial cell markers, and acquires mesenchymal cell markers and properties such as motility, contractile ability, and invasiveness. A complex process that occurs during development and many disease states, EMT involves a plethora of transcription factors (TFs) and signaling pathways. Whilst great advances have been made in both our understanding of the progressive cell-fate changes during EMT and the gene regulatory networks that drive this process, there are still gaps in our knowledge. Epigenetic modifications are dynamic, chromatin modifying enzymes are vast and varied, transcription factors are pleiotropic, and signaling pathways are multifaceted and rarely act alone. Therefore, it is of great importance that we decipher and understand each intricate step of the process and how these players at different levels crosstalk with each other to successfully orchestrate EMT. A delicate balance and fine-tuned cooperation of gene regulatory mechanisms is required for EMT to occur successfully, and until we resolve the unknowns in this network, we cannot hope to develop effective therapies against diseases that involve aberrant EMT such as cancer. In this review, we focus on data that challenge these unknown entities underlying EMT, starting with EMT stimuli followed by intracellular signaling through to epigenetic mechanisms and chromatin remodeling.

Introduction

Epithelial to mesenchymal transition (EMT) is a dynamic reversible process and a fundamental mechanism occurring during embryogenesis and organ development, wound healing and fibrosis, and cancer (1–3). The reverse process (MET; mesenchymal-epithelial transition) is vital for secondary tumor formation and also occurs during embryogenesis with multiple rounds of EMT and MET required for correct formation of complex organs and specialized cellular structures (4, 5). Therefore, understanding EMT is not only beneficial in terms of developing novel cancer therapies, but enables us to fully elucidate the mechanisms behind wound healing and organ fibrosis—processes implicated in diabetic complications (6, 7), heart disease (8), and immunocompromised conditions like cystic fibrosis (9).

Gene regulation controls whether a gene is expressed or silenced, and encompasses transcription factors, epigenetic modifications, chromatin remodeling, higher order chromatin structures (such as looping), and non-coding RNAs e.g. microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). In EMT, transcription factors such as Snail, Zeb1/Zeb2, and Twist, bind to specific promoter and enhancer DNA sequences and work in unison with epigenetic regulators (such as G9a and LSD1) and chromatin remodeling machinery to drive transcription of pro-mesenchymal genes and prevent epithelial gene transcription (3, 10). The chromatin remodelers determine how accessible these DNA sequences are (11); therefore, they determine gene expression during both developmental and disease-related EMT. Like EMT, epigenetic modifications—such as DNA or histone methylation, and histone acetylation—are also reversible, and have been shown to play a pivotal role in EMT regulation, which makes them attractive targets for novel chemotherapeutics (12). Interactions between key EMT transcription factors and enzymes that modify DNA/histones have been reviewed in detail (3, 10, 13, 14).

Nucleosomes (histone octamers) are the basic packaging unit of DNA—the “beads on a string”—which confer 5- to 10-fold compaction of the genome and form arrays that fold hierarchically into higher-order (50-fold and higher) chromatin structures (15). These structures, which include multiple chromatin loops, can repress gene transcription in both stem cells and adult cancer cells, for example the TF GATA4 (16). In addition, PcG proteins and repressive chromatin methylation marks work together to preserve these loops (16). The role of chromatin looping in EMT however is unknown.

Non-coding RNAs represent another layer of epigenetic regulation owing to the susceptibility of their promoters to epigenetic modifications (10, 17). Much is known about the role of non-coding RNAs, such as the miRNA-200s family of microRNAs, in EMT (10, 18–20), with recently published data also showing the involvement of microRNAs [miRNA-151a (21)] and long non-coding RNAs [MYOSLID (22)] in partial EMT. Conversely, the long non-coding RNA NKILA which is upregulated by TGFβ, suppressed TGFβ-induced EMT and tumor metastasis in vivo through negative regulation of downstream TGFβ signaling (23). All of these elements add another layer of complexity and culminate in highly intricate gene regulation.

Unknowns in each area of gene regulation in EMT compromise not only our fundamental understanding of these mechanisms but interfere with our knowledge of EMT pathogenesis. Without this information, we cannot develop critically needed cancer therapeutics targeting EMT, as in addition to driving tumorigenesis and metastasis, EMT confers chemoresistance and helps tumor cells evade destruction by the immune system (24). Advances in the field of regenerative medicine (i.e., cellular reprogramming to restore organ functionality) also rely on deciphering these unknowns. Chemotherapeutics that inhibit DNA methylation (e.g., 5–aza-2′-deoxycytidine, Guadeticabine), histone deacetylation (e.g., Vorinostat, Mocetinostat), and interfere with recognition of acetylated lysine residues (e.g., BRD4 inhibitors such as JQ1, MS417), are promising as they, respectively, restore epithelial phenotypes/reactivate tumor suppressor proteins (10, 13, 25), reduce growth/antagonize Zeb1-mediated miRNA-203 repression (10, 26), and suppress the MYC TF, invasion, and tumorigenicity (10, 25). While these targeted therapies may have a synergistic effect with platinum-based chemotherapies and may sensitize cancer cells to therapies that induce DNA damage (26), these inhibitors are not perfect due to potentially adverse activation of otherwise latent genes, and their somewhat limited effect on solid tumors (10). Here, we discuss unknown epigenetic entities in the gene regulatory network underlying EMT.

Thinking Outside the Cell—Novel EMT Stimuli

Extracellular stimuli are the initiating factors that drive signaling and cellular effects and are often the first point of regulation in disease; pharmacological antagonism of deleterious stimuli or their receptors is often the first treatment option or the only option if the mechanism through which the stimulus mediates its effects are unknown. For example, administration of anti-VEGF is routinely performed in diabetic retinopathy and certain cancers including breast, colorectal, and cervical (27–29). The role of TGFβ in EMT was first shown 25 years ago (30) and is still widely reported; a keyword search for “TGFβ EMT” returns 19,585 results in PMC (27th Sept 2019). Other stimuli known to induce EMT (Figure 1) include epidermal growth factor (EGF) (31, 32), fibroblast growth factor (FGF) (33), hepatocyte growth factor (HGF) (34, 35), vascular endothelial growth factor (VEGF) (36–38), insulin-like growth factor (IGF) (39, 40), WNT (41), Sonic Hedgehog (SHH) (42, 43), BMPs [BMP-2 (44, 45); BMP-4 (46, 47)], TNF-α (48, 49), and hypoxia (32) with the latter thought to promote EMT via epigenetic regulation of DICER; the enzyme involved in miRNA processing (50).

Figure 1

In recent years, researchers have begun to move away from the idea that only growth factors can stimulate EMT. Novel non-growth factor stimuli, which have been implicated in EMT stimulation, include oxalate and Galectin-8. Oxalate—a routine metabolic by-product—and calcium oxalate—whose deposition (Microcalcification type I) is often seen in benign non-malignant breast tissue (51, 52)—induced EMT both in cultured renal cells and in vivo (53, 54). Similarly, oxalate-treated mice presented with highly aggressive undifferentiated mammary tumors and in vitro oxalate induced breast epithelial cell proliferation and expression of the tumorigenic gene c-fos (55). Calcium oxalate mediates its effect via activation of p38/MAPK (56), and oxalate-induced EMT could be prevented by activation of nuclear factor erythroid-derived 2-related factor 2 (NRF2) signaling (57). Galectin-8—a widely-expressed glycan binding protein—stimulated partial EMT; tumors arising from Galectin-8 overexpression bore a mesenchymal phenotype whilst still expressing E-cadherin and maintaining cell polarity (58). Mechanistically Galectin-8 activated FAK to transactivate the EGFR and increased expression of matrix-degrading enzymes (uPA, MMP-13) (58). Importantly the authors elude to the potential involvement of other signaling pathways in facilitating Galectin-8 EMT-inducing effects. It is possible that Galectin-8 may interact with calcium signaling to increase FAK—similar to novel pro-EMT TRPV4 signaling (59) (discussed further in the next section)—or it may require vimentin expression in order to increase uPA (60), or perhaps it relies on integrin αVβ3 signaling to activate FAK (61). Loss of the receptor Neogenin 1 (a member of the DCC/Frazzled/UNC-40 family) also induced partial EMT in intestinal epithelial cells, via PI3K and MAPK signaling, and extracellular matrix (ECM)-receptor interactions (62).

Despite the novel EMT stimuli above, there are still unanswered questions. It is possible that there are other seemingly harmless metabolic by-products and binding proteins that stimulate EMT. How oxalate promotes pro-cancerous gene expression, and whether it interacts with HATs or other histone modifying enzymes remain to be investigated. Knowing that these stimuli can induce EMT is just the first step in understanding how non-canonical signals can cause EMT. In addition, deciphering the cellular markers and epigenetic signatures associated with partial EMT is crucial. Despite the similarities in the step wise process (the cadherin switch, for example) and with the endpoint ultimately unchanged, it is conceivable that for example, hypoxia-induced EMT may be different from TGFβ-induced EMT in terms of the underlying epigenetic signature and responsiveness to treatment; Cursons et al. showed that where the primary EMT stimulus was hypoxia, treatment directed cells to acquire a more aggressive mesenchymal phenotype (32). Thus, if we were to develop and evaluate therapeutics that selectively target different EMT stimuli as opposed to common downstream targets, perhaps this could enable us to minimize pathological conditions and/or adverse effects which would translate to prognostic differences in patients. Having said this, pre-clinical research of EMT-specific therapeutics is ongoing and yielding promising data. Regorafenib—a multi-kinase inhibitor pre-approved as a second-line treatment in metastatic CRC—displayed potent anti-EMT effects on invasion and metastasis in vitro and in vivo by inhibiting TGFβ-induced STAT3 phosphorylation (required for Twist1 and Zeb1 activation) (63).

Antibody-mediated approaches are among the frontrunners in anti-EMT therapy. For example, an anti-MMP9 antibody—which targets an enzyme involved in EMT-mediated ECM remodeling in cancer—increased survival and reduced metastatic burden and the EMT marker vimentin in an in vivo model of pancreatic cancer (64). Similarly, in an in vivo breast cancer model a monoclonal antibody that blocks active MMP9 inhibited spontaneous and experimentally induced lung metastases (65). Clinical trials using an anti-MMP9 antibody (Adecaliximab) alone or in combination therapies are ongoing. It is hoped that these agents will perform better than previously tested broad-spectrum MMP9 inhibitors, which failed in clinical trials due to dose-limiting side effects (64).

In prostate cancer a monoclonal antibody targeting N-cadherin reduced invasion, metastasis, and proliferation of cancer cells as well as Akt activity (66). However, as N-cadherin is expressed in the heart, peripheral nerves, and liver, adverse off-target effects are a huge concern (66).

It is assumed that upregulation of E-cadherin would be beneficial in cancer, given its downregulation in many cancers. In some instances, this is true; in RCC cell lines small activating RNA stimulated E-cadherin expression and subsequently inhibited cell migration and invasion, and downregulated vital pro-EMT genes such as Zeb1 and vimentin (67). However, E-cadherin was required for invasive ductal carcinoma cell survival and metastasis in multiple in vivo models of breast cancer (68), finally explaining why E-cadherin is often observed in patients with breast cancer. These data also highlight the potential pitfalls associated with assumed pro-/anti-EMT markers. In addition, such therapeutics can be limited by poor tissue penetration and short biological half-lives (69), and antibody therapeutics are often very expensive to produce and may not be covered by an individual's health insurance.

Despite copious research papers that detail microRNAs that promote or inhibit cancer development, the translation of these data to tangible microRNA drugs is lacking. While no Phase 3 trials are ongoing in this area, new candidates (like RGLS5579 for glioblastoma) are entering the early phases of clinical trials (70), and targeted inhibition of microRNA-155 and microRNA-21 has successfully resensitized tumors to chemotherapy in lung and breast cancers, respectively (71, 72).

EMT therapeutics that repurpose existing FDA-approved drugs is most exciting, as it significantly reduces the translational time of such therapeutics. A comprehensive bioinformatics analysis of pre-approved drugs has proposed and validated various drug combinations, like IKBK and SRC kinase inhibition together with HDAC inhibition, to hamper EMT (73). Often, scientists researching novel EMT drug candidates focus on preventing an epithelial cells transition to an invasive mesenchymal cell, or inducing MET to revert to a normal epithelial state. However, MET may in fact enhance metastatic outgrowth (74, 75). Recently, Ishay-Ronen and colleagues demonstrated a novel method of preventing cancer progression that exploits the plasticity of cancer cells (76). By transdifferentiating post-EMT mesenchymal cancer cells into functional post-mitotic adipocytes—using a combination of pre-approved drugs (Rosiglitazone and a MEK inhibitor)—primary tumor growth and metastasis was repressed (76). Importantly, epithelial cells were immune to adipocyte transdifferentiation (76), highlighting the specificity of this targeted therapeutic. Other novel EMT therapeutics include Antrodia salmonea—a fungus indigenous to Taiwan and known for its anti-cancer properties (77). In vitro, Antrodia salmonea significantly reduced invasion and reversed EMT by modulating NFκB and WNT/β-catenin signaling, and in vivo treatment with Antrodia salmonea reduced breast cancer cell-induced lung metastasis (77).

In Tune With EMT Intracellular Signaling

EMT is dependent on the concomitant activity of multiple signaling pathways (Figure 2), which are constantly firing and fluctuating, with turnover time for signaling molecules sometimes infinitesimal [e.g., the half time of HIF-1α clearance is 3–6 min in normoxia (78)]. Positive and negative feedback loops are also incorporated into intracellular signaling pathways, which also rarely work independently and often regulate each other; TGFβ can promote HIF-α expression independent of PI3K by encouraging HIF-1α/HIF-2α translation (79). Downstream TGFβ signaling is the predominant intracellular signaling pathway in EMT. However, as detailed above different stimuli utilize TGFβ signaling and other pathways such as NFκB, YAP/TAZ (Hippo pathway), PI3K/Akt, ERK/JNK, Wnt, Notch, and JAK/STAT3.

Figure 2

While there are copious research papers and reviews detailing the separate roles of these pathways in EMT [see (24, 80–85)], a systems biology approach—or simply data-sharing between groups working on different pathways—would facilitate further elucidation of the intricate nature of signaling pathways and their molecules in EMT. For example, Akt-mediated NFκB activation has been implicated in EMT (86) and our lab performed comprehensive genome-wide analysis of the active open—transcription facilitating—chromatin mark H3K27ac and subsequent gene expression in mammary epithelial cells undergoing EMT (87). We discovered that ERK signaling was essential for epigenetic reprogramming underlying characteristic EMT-related gene expression and phenotypic changes; ERK inhibition prevented the loss and gain of H3K27ac at epithelial and mesenchymal genes (i.e., repression and expression, respectively) (87).

Unraveling inter-pathway regulation in EMT and deciphering what signaling pathways are required for different stages/steps of EMT (e.g., initiation, progression, maintenance, the cadherin switch, loss of cell polarity and other phenotypic alterations) is of vital importance. Recently, the DEPTOR (DEP domain containing mTOR interacting) protein which normally inhibits mTOR signaling, stimulated partial EMT in HCC cells by activating TGFβ-Smad3/4-Snail signaling through mTOR inhibition (88). Similarly, in vitro mimicking of ECM organization showed that the way the ECM is arranged could trigger partial or full EMT (89). This process was dependent on YAP activation and subsequent YAP-mediated feedback; Wilms Tumor-1-YAP mediated E-cadherin downregulation, and YAP-TRIO-Merlin-mediated Rho GTPase regulation, which, respectively, loosened cell-to-cell contacts and increased cell migration, compromising epithelial sheet integrity, facilitating EMT, and promoting invasion (89). The location of this phenomenon, i.e., several cells away from the sheet edge, or at the sheet edge itself, determined whether EMT was partial or full, respectively (89). Conversely, single-cell RNA sequencing of untreated epithelial cells vs. those treated with TGFβ showed continuous waves of gene regulation in EMT as opposed to discrete “partial” stages (90). The authors showed that deleting/interrupting key signaling moieties or events can cause cells to build-up at regulatory “checkpoints” that mimic “partial” stages, and enrich a particular pattern of gene expression in said cells which creates the impression of a stable intermediate phenotype (90).

It is also essential that the roles of various signaling pathways—like the aforementioned FAK signaling involved downstream of Galectin-8 (58)—in mediating global transcriptional changes through epigenetic regulation, which are required for EMT, be clarified. That said there are publications that are beginning to decipher these complex interactions. Of note, our laboratory was among the first to report TGFβ and JNK signaling in tandem in EMT; TGFβ signaling via canonical Smads was required for EMT initiation whereas JNK signaling was necessary for EMT to progress to fruition (91). Similarly, an Australian group showed that non-canonical ERK1/2 was needed for initiation but not progression of TGFβ-induced EMT in the rodent eye (92).

The importance of calcium signaling in EMT has gained considerable momentum in recent years, not only because of the discovery of calcium oxalate as a novel EMT stimuli, but because the Ca2+-binding protein calreticulin (CRT) was shown to be increased by—and able to regulate—TGFβ-induced EMT in vitro (93). Similarly, the TRPV4 ion channel was shown to mediate calcium-dependent downregulation of E-cadherin in breast cancer via activation of Akt signaling (59). Given the fundamental importance of calcium signaling, there are obvious caveats to widespread calcium chelation/calcium channel blockade—similar to widespread DNA methyltransferase (DNMT) inhibition. That said the development of highly specific calcium chelators has the potential to not only reduce EMT but to potentially do so with minimal adverse effects on the patient. The unknown here is whether the beneficial effects on EMT are (a) due to calcium blockade alone or off-target effects on other signaling pathways, and (b) enough to outweigh any pro-EMT effects that may arise from calcium blockade. For example, in addition to reducing E-cadherin TRPV4 activation also augmented FAK phosphorylation (similar to Galectin-8, above), reduced β-catenin and fibronectin-1, and increased expression of the cytoskeletal protein talin-1 (59), an essential protein in maintaining the structural integrity of focal adhesions (94). How TRPV4 induces EMT when it reduces β-catenin and fibronectin, and the key EMT genes TRPV4 regulates to cause EMT without β-catenin and fibronectin, are still elusive.

Non-canonical interactions and lesser-known signaling pathways in EMT are an additional unknown. For example, interactions between TGFβ and the cytoskeleton are emerging (95, 96), with the histone demethylase (HDM) JMJD5 required for cytoskeletal stabilization and inhibition of TGFβ-induced migration in lung cancer cells (95). In terms of lesser-known signaling pathways that are functional in EMT, MNK1/2-eIF4E signaling (97), LOXL2-IRE1/XBP1 signaling (98), and miRNA-20a-FBXL5/BTG3 signaling (99) are examples of seemingly isolated signaling pathways that have recently been implicated in EMT, yet other remote pathways might be involved. Inhibition of MNK1/2-eIF4E signaling using a novel retinamide yielded an impressive trifecta of anti-growth effects, inhibition of EMT, and androgen receptor signaling (97). Overexpressed LOXL2 (lysyl oxidase-like 2) accumulates in the endoplasmic reticulum (ER) where it forces detachment of heat shock protein 5A (HSP5A) from IRE1/XBP1 to activate the IRE1/XBP1 signaling pathway, which confers expression of notable EMT-TFs such as Snail, Zeb2, and Slug in an XBP1-dependent manner (98). However, given the fact that IRE1 inhibition can block XBP1-mediated TF expression (98), more research is needed to decipher this mechanism. FBXL5/BTG3 are direct miRNA-20a targets that are silenced to enable miRNA-20a-mediated EMT and invasion (99), however the precise role of FBXL5 signaling in EMT requires further research; FBXL5 overexpression reduced Snail protein levels (100), but also supported tumorigenesis by negatively regulated PTEN while promoting PI3K/Akt and mTOR phosphorylation and expression (101). The above data on FBXL5 agrees with previous research in our lab, where we discovered that FBXO32—another F-box protein—was pivotal in upstream EMT regulation not only in tumor metastasis, but in neuronal development also (102). FBXO32 directly ubiquitinated CtBP1 causing its stabilization and nuclear retention, which created a suitable microenvironment for EMT progression by facilitating epigenetic remodeling and transcription of CtBP1 target genes (102). In line with these findings, FBXO32 was amplified in metastatic cancers, and its depletion in vivo inhibited tumor growth and metastasis (102). These data highlight how important it is for scientists today to challenge pathways that were believed to be futile in EMT as well as those that are routine.

Factoring in Transcriptional Regulation in EMT

Transcription factors play important roles in cell-fate decisions, and a hierarchy of TF signals may influence whether a cell is epithelial, intermediate, or mesenchymal. Similarly, TFs may operate in a dose-dependent manner, for example, Twist may be required in nanomolar concentrations whereas Snail may be required in micromolar concentrations; indeed, in an EMT time course Twist was transiently detected whereas neither Snail nor Slug were significantly detected (103). Similarly, SNAIL proteins were shown to promote EMT with different potencies in human mammary epithelial cells (104). This is a novel exciting area of research; however, it is beyond the scope of this review. As the intermediaries between cellular signaling and chromatin, these DNA binding proteins guide the epigenetic machinery to their target sites which facilitates chromatin landscape changes at promoter and enhancer elements to drive downstream activation and repression of mesenchymal and epithelial genes, respectively (3, 10). Much is known about the core TFs involved in EMT (Snail, Zeb1/2, and Twist) but a large number of TFs are required for EMT.

A vast amount of EMT research has focused on TF involvement in the latter stages of EMT, but until recently, little was known about the transcriptional networks that trigger EMT. Newly published data shows that EMT involves a temporal hierarchy of collaborative transcriptional networks (105). This predicted network operates between TFs and between TFs and microRNAs and is composed of 46 (co)transcription factors and 13 miRNAs that were critically required for EMT in NMuMG cells (105). We are also beginning to decipher the requirement of different TFs for EMT initiation, maintenance, and progression (Figure 3). For example, the TF NRF2 delays the transition of a cell to a full mesenchymal phenotype; it maintains the hybrid epithelial/mesenchymal (partial/intermediate EMT) state (106). Similarly, research from our lab has shown that JNK-induced TFs and subsequent signaling are not required for EMT initiation, but was essential for progression of phenotypic hallmarks of EMT (91). Our lab has identified novel JNK-induced TFs that are required for EMT, are highly expressed in invasive cancer cells, and induced during neuronal development (91). These data are pivotal in the fight against EMT because the authors do not examine these novel TFs individually in EMT; they also define their role(s) in EMT that occurs in neuronal development.

Figure 3

An unknown in this area, is the existence of TFs that do more than just control gene expression—perhaps TFs can perform secondary functions, such as chromatin remodeling (Figure 3), or mediate epigenetic regulation in EMT. In terms of TFs that exhibit auxiliary properties, our lab identified NeuroD1 as a pioneer factor; it recognizes and binds to its target sites and drives transcription of neuronal/EMT-related genes (such as Hes6 and Dll3, Snai2 and Twist1, respectively) regardless of the chromatin state (open or closed) or cell type (e.g., ESCs and differentiated fibroblasts) (107, 108). NeuroD1 is not alone in its pioneer TF abilities; FOXA TFs (FOXA1, FOXA2, FOXA3) (109, 110) and GATA3 (109) are also pioneer factors that determine cell fate. Heat shock factor 1 (HSF1) which induces HSPs is another pioneer factor with a secondary function in recruiting DNMT3A to suppress miRNA-137 and promote carcinogenesis (111), and perhaps HSF1 is also involved in HSP5A-mediated regulation of LOXL2-IRE1/XBP1 signaling. Despite these advances, the specific involvement of pioneer TFs in EMT in cancer remains to be seen.

TF that mediate epigenetic alterations are coming to the forefront of the field; Zeb2 employs DNA methylation to repress RAB25—a small Rab GTPase with a potential role in epithelial polarity—and E-cadherin, and increased SIRT-1-mediated H3K9 deacetylation at both promoters to maintain this suppression (112). FOXD3 both permits and prevents H3K27ac of regulatory elements and acts as a pioneer factor during neural crest (NC) development to prime NC factors (e.g., snai1b, twist1b), acts upstream of pro-EMT factors, and during NC EMT FOXD3 mediates a cadherin switch (decreased N-cadherin and increased cadherin 7) to modulate cell adhesion (113, 114). BPTF (bromodomain PHD finger TF), a TF which is also the largest subunit of the NURF chromatin remodeling complex [a member of the ISWI remodeling family (11, 115)], was increased in HCC where it inferred poor survival and correlated with high vimentin and low E-cadherin expression (116). These data show us that TFs are more than a “one trick pony”—they can influence the epigenetic signature of a cell. It was accepted that all relevant EMT-TFs had been identified but given the discovery of novel EMT-TFs in recent years and the fact that we still can't resolve EMT, perhaps there are unknown EMT-TFs (capable of altering a cells epigenetic state) and unknown ENT-TF targets that are yet to be discovered. Sox4 was known to play a role in EMT (117), but it was not until the following year that its direct transcriptional targets—like EZH2, fibronectin, N-cadherin—and role as a master regulator of EMT were elucidated (118). EZH2 in turn suppresses the tumor suppressor hepatocyte nuclear factor 1β (HNF1B) which normally represses Slug (119). Similarly, Sox8-mediated chemoresistance and stemness in tongue squamous cell carcinoma was only recently shown to involve Frizzled-7/Wnt/β-catenin signaling (120).

Perhaps alternative splice isoforms of existing TFs are yet to be discovered. For example, splice variant 1 (SV1) is a truncated isoform of KLF6 that has no zinc finger domains, yet it promotes tumor migration, and is thought to stimulate EMT in HCC (121). Hepatocyte nuclear factor 4α (HNF4α) has alternative isoforms that both stimulate (HNF4α7, 8, 9) and repress (HNF4α1, 2, 3) cancer development (121–123). We also cannot rule out the possibility of alternative TF splice isoforms in epithelial and mesenchymal cells. Their existence and how they influence cell signaling in EMT remain elusive. Indeed, extracellular ligands, DNA/histone modifying enzymes, and chromatin remodeling proteins may also be subjected to alternative splicing in EMT. Non-TF proteins could also be subjected to alternative splicing, to enable pro-EMT TFs. Recently, exon skipping in FLNB (an actin-binding protein) was shown to induce EMT by releasing the pro-EMT TF FOXC1 (124). This alternatively spliced isoform of FLNB also correlated with EMT gene signatures in basal breast cancer samples (124).

In addition, there may be TFs that we believe are fully elucidated, and so are not examined in the context of EMT. For example, GLI TFs are the primary mediators of developmental Hedgehog-GLI signaling pathway, which is mostly inactive in adults (except for in stem cells) (125), but GLI inhibition was found to block EMT in pancreatic cancer stem cells through reversion of the typical EMT cadherin switch and blockade of EMT-TFs (126). Together these data make the HH-GLI pathway an attractive—previously unthought-of—target in EMT therapy and add to the rationale for examining TFs in other developmental pathways, but it has taken over a decade for such pathways to become a focus of therapeutics—which is perplexing given that TFs necessary for development are often implicated in EMT.

We also cannot rule out the possibility of TFs forming fixed complexes with epigenetic proteins or non-histone proteins in EMT. For example, the non-histone chromatin protein HMGA1 forms a complex with the TF FOXM1 which stabilizes FOXM1 in the nucleus and increases expression of shared target genes like VEGFA to promote angiogenesis, inferring a negative prognosis (127). This is not the only HMG protein implicated in EMT; the pro-EMT role of HMBG-1 is discussed below. Perhaps TFs are epigenetically altered in EMT to silence or amplify their effect. Take MYC-GATA3/ESR1 TFs for instance; MYC overexpression increased MYC enrichment and reduced active histone marks (H3K27ac, H3K4me1/3) at regulatory elements for GATA3 and ESR1, resulting in cellular dedifferentiation i.e., a stem cell-like state (128). These data were validated in breast cancer patients where there was an inverse relationship between MYC overexpression and GATA3/ESR1 gene levels (128). It is plausible that there are other TFs that interact like this in EMT.

Epigenetic Mechanisms Involved in EMT—Room to Explore

Histones are the primary component of chromatin. Positioning DNA around histone octamers—nucleosomes—to form chromatin is essential to maintain the integrity of the genome; chromatin prevents DNA strand entanglement, but also dynamically regulates DNA replication and gene expression (129, 130). Extracellular stimuli, intracellular pathways, and transcription factors are subject to variation between patients and between cancers, and chromosomal instability promotes cancer (131), but the DNA is the same in all cells of the organism (132) and mechanisms and regulators of chromatin condensation are well-known (133). This makes chromatin the ultimate platform for action. Epigenetic—“above genetic”—modifications alter the genetic read-out of a cell, and include DNA methylation, histone modifications, and chromatin higher order structures (such as looping), which in collaboration with chromatin remodelers determine chromatin accessibility.

Establishing the epigenetic state involves epigenetic readers, writers, and erasers which recognise, create, or remove epigenetic modifications respectively (134). A patient's epigenetic state is therefore both dynamic and stable, and is involved not only in disease pathogenesis but in their response to treatment and their rates of disease-free survival and recurrence (135–138). Therefore, epigenetic regulators are prime therapeutic targets, and understanding epigenetic mechanisms of regulation would pave the way for novel therapeutics and personalized cancer medicine. We know that EMT-TFs guide the epigenetic machinery to target promoters/enhancers, but we do not know the mechanism behind this; i.e., how cells decide which loci are targeted during EMT initiation, progression, and maintenance.

Single-cell analysis has shown that during development progenitor cells display epigenetic heterogeneity (139). Specifically, the pre-EMT and delaminating crest (undergoing EMT) generate migrating progenitor cells whose heterogeneity is associated with transcriptional properties of early genes from competing downstream cell fates, which are activated when NC cells undergo EMT (139). The authors also note that mesenchymal potential may be established as early as delamination; lone overexpression of Twist1 was able to drive trunk NC toward a mesenchymal fate rather than the traditional neuronal fate (139). These data provide us with a better understanding of developmental NC EMT which in turn aids our understanding of NC-derived cancers such as melanoma and glioma, and perhaps such heterogeneity is present in other cancers (139, 140).

Epigenetic regulation of EMT (Figure 4) has mainly focused on histone methylation/acetylation, with additional studies detailing the roles of other histone modifications such as phosphorylation (141–143), ubiquitination (144–146), citrullination (85, 147–149), SUMOylation (150–152), and biotinylation (153) in EMT. Histone modifying enzymes are dynamic and diverse. Established enzymes [reviewed in (3, 10)] are involved in DNA methylation (DNMTs), histone (de)methylation (HMTs, HDMs), histone (de)acetylation (HATs, HDACs), and ubiquitination (E3 ubiquitin ligases). Despite the wealth of knowledge regarding these enzymes, we have much to learn. For example, class I HDAC enzymes generally promote tumorigenesis, and class IIA may promote or impede cancer development; however it was only recently discovered that HDAC5 induced anti-proliferative or pro-EMT effects depending on the cell line in which it was overexpressed (154).

Figure 4

Unsurprisingly a number of these enzymes contain methyl-lysine binding motifs, which curiously differ between enzymes; DNMT3A contains a PWWP domain to read H3K36me3 (155), ankyrin repeats in the histone methyltransferase (HMT) G9a enable H3K9me1/2 binding (156), and a double Tudor domain exists in the HDM JMJD2A for H3K4me3 and H4K20me3 binding (157). Even though these binding motifs are crucial for correct chromatin recognition—needed for enzymatic effects on chromatin methylation state—the importance of these different domains in EMT remains unknown; we do not know why there are three distinct methyl-lysine binding motifs among histone modifying enzymes, or whether they play a causal role in EMT development or not.

PWWP domains are distinct from the catalytic domain in DNMT3A (155). Missense mutations in the PWWP domain (W330R) abolish H3K36me2/3 binding and cause DNA hypermethylation at Polycomb-regulated regions in patients and in vivo (158). This is associated with reduced H3K27me3 and H3K4me3 bivalent marks, and modified chromatin accessibility at key developmental regulators (e.g., SOX and HOX family members, FOXA1, NEUROG1/2) (158). The implications for such mutations in EMT are still unknown. Perhaps mutations in the PWWP domain of DNMT3A confer increased methylase activity and allow the mutant to methylate polycomb regions, thus preventing PRC2 binding and EZH2-mediated H3K27me3 at epithelial genes as suggested by Heyn et al. (158). Alternatively, maybe methylase or other DNA recognition/binding motif activity is decreased upon PWWP mutation, allowing mesenchymal gene expression. The PWWP domain might even interact with non-histone proteins in EMT; however whether this is strengthened or weakened in mutant DNMT3 remains to be investigated. Whether mutant DNMT3A has enhanced or diminished recruitment by the aforementioned pioneer factor HSF1 also remains to be seen. Studies that examine human cancers for the presence of these and other PWWP mutations would be worthwhile, as the PWWP binding motif is highly conserved in human hepatoma-derived growth factor (HDGF) which is overexpressed in a number of human cancers and is involved in PI3K signaling (159). We cannot rule out a causative—or at the very least a contributing—role for PWWP domain mutations in EMT development in cancer, thus deciphering the unknowns that still surround the PWWP domain is of great importance.

The methyl-lysine binding motif in the HMT G9a contains ankyrin repeats; the rationale behind ankyrin repeats over a PWWP domain is unknown. Perhaps each motif bestows different effects on epigenetic regulation of EMT. In EMT G9a interacts with Snail which recruits it to the CDH1 promoter (160). Enhanced in hypoxia, G9a activity is beneficial to cancer cell survival and G9a can methylate non-histone proteins (161), like the ATPases Pontin and Reptin (162). The functional importance of the ankyrin repeats was only recently discovered. Levels of H3K9 mono/di/tri-methylation were analogous in ESCs expressing either wild-type G9a, G9a bearing a mutation in ankyrin repeats, or G9a lacking ankyrin repeats (163). However, the HMT activity of G9a/GLP is dependent on the ankyrin repeats (164). These data illustrate that these enzymes are more than just their catalytic activity. In terms of G9a-Snail interactions in EMT, the role of the ankyrin repeats in facilitating non-histone protein (e.g., E-cadherin) methylation required elucidation. It is plausible that there are G9a variants—like the variant that skips exon 10 (165)—that are alternatively spliced in exons pertaining to the ankyrin repeats, which may be present and causal in EMT. In line with this, a novel splice isoform of the arginine methyltransferase PRMT1 which lacks exons 8/9 (that encode for the dimerization arm, essential for enzymatic activity) was increased in cancer cell lines and induced by Snail (166). Similarly, PRMT9 elicited pro-invasive and metastatic effects via Snail and the PI3K/Akt pathway, which was validated in clinical HCC samples (167). Given the high stability of histone modifications in bodily fluids (168), methylated arginine residues could be developed as a novel prognostic biomarkers/therapeutic targets.

The role of Tudor domains (found in the HDM JMJD2A) in epigenetic regulation of EMT is yet another unknown. In addition to recognizing and binding H3K4me3 and H4K20me3, the two tandem Tudor domains in JMJD2A bind H3K9me3 and H4K20me2 which confer roles for JMJD2A in initiating and preventing transcription (169). As there are two Tudor domains, these conflicting functions might be localized to a specific domain, or the two Tudor domains might have opposing effects on EMT. Further work is required to determine whether JMJD2A has a pro- or anti-EMT effect given its ability to silence and active genes. Given the aforementioned involvement of fellow Jumonji family member JMJD5 in inhibition of TGFβ-induced migration in lung cancer cells (95), it is plausible that JMJD2A has a similar anti-EMT effect, however this claim warrants further research. In addition, to stabilize chromatin binding and mediate its epigenetic effects—and oncogenic effects—JMJD2A must be SUMOylated at K471 (170). We know that lysine residues can accept different epigenetic modifications, but there is no hard and fast rule that the enzymes that perform these histone/DNA modifications are exempt from modification themselves; For example, phosphorylation of G9a on Ser569 is crucial for its recruitment to damaged DNA (171).

Remodeling Our Understanding of Chromatin Machinery in EMT

Chromatin remodeling can involve nucleosome repositioning, swapping, displacement or even translocation to a fragment on a neighboring strand of DNA, as well as histone replacement (11, 172). In addition to roles in nucleosome positioning and DNA dependent biological processes such as repair and replication (173), remodelers are crucial determinants of chromatin accessibility and subsequent gene expression (11). Four major chromatin remodeling families are characterized; SWI/SNF, ISWI, CHD, and INO80 (11). Genes encoding components of SWI/SNF (e.g., BRG1) are among the most common targets of mutation in cancer; ~20% of human tumors were shown to contain mutations in at least one member of this complex (11). Despite this alarming statistic, mechanisms of epigenetic regulation by chromatin remodeling proteins and histone chaperones—in particular, how such regulation may be detrimental to our health, as is the case in EMT-related tumorigenesis—are largely overlooked.

Known chromatin remodelers with functional roles in EMT (Figure 5) have been reviewed see (174) and include the NuRD subunits MTA1 and MTA3 within the CHD family, the BPTF subunit of the ISWI family member NURF (116), and the BAF250/ARID1, BRG1, and hBRM subunits of the mammalian SWI/SNF complex (174, 175). Interestingly, the combined loss of BAF250A/ARID1A and gain of expressed mutated PI3K subunit PIK3CAH1047R results in partial EMT in the endometrial epithelium (176). Resistance to ER antagonists in breast cancer was recently attributed to loss of ARID1A, which reduced HDAC1 activity and increased H4K acetylation—sensitizing the cancer cells to BRD4 inhibition (177). Nucleophosmin 1 (NPM1) is another well-studied histone chaperone [reviewed by (178)] with a role in EMT/invasion (179–181).

Figure 5

In terms of nucleosome structure, the FACT (FAcilitates Chromatin Transcription) histone chaperone complex is a heterodimer consisting of SSRP1 and SUPT16H that has established roles not only in nucleosome destabilization and formation, but in the replacement of histones with histone variants, and FACT also prevents unwanted histone movement during transcription (182). FACT subunits were shown to be overexpressed in breast cancer and pharmacological entrapment of FACT within chromatin—which reduced FACT activity—had positive (dose-dependent) effects on murine survival, prevented tumor onset and delayed progression in vivo (183). Given these data, our understanding of the EMT-promoting effects of the chromatin remodeling machinery is lacking. In human intestinal cell lines the FACT subunit SUPT16H positively correlated with epithelial markers such as E-cadherin and showed an inverse relationship with the expression of classical mesenchymal markers like Zeb1 (3). Crystallographic examination of the FACT subunit Spt16 [isolated from yeast, the middle domain (-M) in particular] showed that a double pleckstrin homology (PH) domain exists in Spt16-M (184). Although analogous studies with SUPT16H are required, these data suggest that like its homolog, SUPT16H may contain PH domain(s) to bind to proteins other than histones or to facilitate intracellular signaling. Elucidating the role of PH domains in chromatin remodeling proteins could uncover previously unknown functions of histone chaperone proteins in EMT—their role in regulating chromatin accessibility may be just one avenue through which they promote EMT. Spt16-M could bind to H3-H4 (184), and therefore may influence the methylation/acetylation state of key lysine residues on H3-H4, possibly through interacts with DNMT3A, G9a, JMJD2A, or other epigenetic modifying enzymes, which may increase chromatin accessibility at epithelial gene promoters/regulatory elements and vice versa for mesenchymal genes. The second FACT subunit SSRP1-M was initially thought to lack histone binding (185), however it was later shown to bind H3-H4 as well as H2A-H2B (186). In vivo the SSRP1 subunit enhanced xenograft tumor growth/proliferation and SSRP1 overexpression in vitro promoted EMT (187). Mechanistically, miRNA-28-5p was implicated in upstream negative regulation of SSRP1 (187), however given the discovery of PH domains within Spt16 and SUPT16H-H3/H4 binding, it is reasonable to suggest that SSRP1 promotes EMT via epigenetic regulation of key genes, albeit further research is required.

The histone chaperone SUPT6H was found to be indispensable in estrogen-dependent breast cancer cells in terms of maintaining chromatin structure, facilitating estrogen-mediated transcription, and suppressing H3K27me3 on lineage-specific genes (188). However, in vitro murine Spt6 was shown to offset H3K27me3 by facilitating the H3K27 demethylase KDM6A (a.k.a. UTX, another Jumonji family member) (189). Consequently, Spt6 promoted differentiation and muscle gene expression in skeletal muscle cells (189). UTX was later shown to epigenetically repress the EMT-TFs Snail and Zeb1/2—independent of H3K27 demethylation—via decreased H3K4me2 and H3 acetylation at their promoters (190), with these anti-EMT effects in agreement with previously described data on JMJD5. In contrast, KDM5B overexpression increased cell proliferation, positively correlated with EMT markers, and promoted aggressive tumors in lung cancer (191). These data highlight just one facet of the intricate relationship between chromatin remodeling machinery and epigenetic regulation and illustrate the need for further research into how chromatin remodeling proteins may contribute to EMT.

HMGB-1 (high-mobility group box 1); a well-studied chromatin-binding nuclear protein that acts as a chromosome guardian/DNA chaperone and has immune/inflammatory functions [all of which have been extensively reviewed by (192)], was shown to promote EMT by upregulating MMPs (-1/-3/-10) via RAGE/NFκB pathway (193), and activating the TLR4/p38/NRF2 pathway to facilitate HMGB-1-mediated downstream EMT signaling (194). However, the epigenetics regarding HMGB-1 are unknown. Perhaps HMGB-1 itself epigenetically regulated, given the fact that its promoter coincides with a CpG island (195). Maybe HMGB-1 influences the epigenetic regulation of EMT target genes (epithelial or mesenchymal), or its DNA chaperone activity could promote/prohibit potential epigenetic regulation of target genes by competing with other chromatin proteins for the same chromosomal DNA sites as suggested by Spada et al. (196). Its EMT-promoting effects are somewhat localized to targeted interaction with its 3′ untranslated region (197, 198)—whether the crucial roles of 3′ UTRs in translation efficiency, mRNA stability and subcellular localization (199) play a role in HMGB-1-induced EMT remains to be studied. Given its ubiquitous expression it is possible that HMGB-1 is merely a ticking time bomb which can silently instigate EMT via a multitude of signaling pathways under the guise of other stimuli; HMGB-1 can signal via numerous receptors including but not limited to TLRs, RAGE, and integrins (192), so perhaps the EMT-inducing effects of HMGB-1 can be mirrored by other stimuli that activate these receptors and/or these downstream signaling cascades.

Chromatin Assembly Factor 1 (CAF1) consists of three proteins—p150, p60, and p48—and is necessary for preserving chromatin structure in our cells (200, 201). A novel role for CAF1 in EMT was recently uncovered, where CAF1 was implicated in cellular invasion and motility, and siRNA-mediated CAF1 depletion (specifically the p150 subunit) promoted the development of a Slug and/or claudin-guided EMT-like phenotype (202). Given its primary role as a histone chaperone, CAF1 may facilitate EMT via alterations in chromatin remodeling at key EMT genes, i.e., its depletion may enhance accessibility at mesenchymal genes. While these data implicate CAF1 depletion in cancer development, in a protein complex each subunit needs to be studied separately first and then as a whole. The p150 subunit was highly expressed in HCC tissue and epithelial ovarian cancer where it was associated a poor prognosis (203, 204). Similar data were obtained regarding the p60 subunit in prostate and lung cancers (205, 206), however virtually no information is available on p48, as it has not yet been identified in humans. As informative as these data may be, they do not address the gaping hole of how and why these CAF1 subunits are involved. Surely, there are epigenetic mechanisms involved, but as of right now these are unknown.

Conclusion

EMT is a dynamic multifaceted process occurring during development, tissue/organ repair, and disease, involving a vast network of signaling molecules working in unison and/or against one another (Figure 6). Just because there are different sub-types of EMT, does not necessarily mean that the stimuli, intracellular signaling pathways, TFs, epigenetic mechanisms, and chromatin remodeling machinery underlying developmental EMT, wound healing/fibrotic EMT, and cancer-related EMT are dissimilar. There must be some common ground between the sub-types and between partial and full EMT. Moreover, the partial/intermediate phenotype is of particular interest given recent single-cell sequencing data depicting continuous waves of gene regulation in EMT as opposed to discrete “partial” stages.

Figure 6

Novel stimuli and intracellular pathways, undiscovered TFs and DNA/histone modifying enzymes, and the role of chromatin remodelers in EMT are huge unknowns in EMT. Auxiliary TF functions and the role of different sets of TFs involved in EMT (initiation versus progression etc.) warrant further investigation, and inter- and intra-tumor epigenetic heterogeneity and the impact of a cancer patient's epigenetic state are other compelling areas of research. To date, the majority of EMT research has focused on individual sub-types; data examining them as one process that occurs at three distinct “time points” is lacking. The challenge for future research therefore lies in (a) examining EMT concomitantly in disease and non-disease states, (b) looking at the interplay between canonical and non-canonical stimuli, TFs, and pathways involved in EMT, and (c) elucidating the roles the chromatin remodeling machinery and alternative splicing in phenotype determination during EMT, all with the aim of unraveling the complexity of the gene regulatory network underlying EMT. The data highlighted in these sections illustrate that researchers have begun to challenge these unknowns, but more work is needed to expand our knowledge and ultimately advance our ability to cure cancer.

Statements

Author contributions

DL and VT worked on the conceptual framework and generated the final version for submission.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

    Abbreviations

  • AKT

    Protein kinase B

  • ARID1

    AT-rich interaction domain 1

  • BMP

    bone morphogenetic protein

  • BPTF

    bromodomain PHD finger TF

  • BRD4

    bromodomain containing 4

  • BRG1, Brahma-related gene 1, a.k.a. SMARCA4, SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a

    member

  • BTG3

    BTG anti-proliferation factor 3

  • CAF1

    chromatin assembly factor 1

  • CHD(1)

    chromodomain helicase DNA-binding (protein 1)

  • CRT

    calreticulin

  • DCC

    deleted in colorectal cancer

  • a netrin receptor
  • DEPTOR

    DEP domain containing mTOR interacting protein

  • DNA

    deoxyribonucleic acid

  • DNMT

    DNA methyltransferase

  • ECM

    extracellular matrix

  • EGF

    epidermal growth factor

  • EMT

    epithelial to mesenchymal transition

  • EGFR

    epidermal growth factor receptor

  • EIF4E

    eukaryotic initiation factor 4E

  • ER

    endoplasmic reticulum

  • ERK

    extracellular signal-regulated kinase

  • ESR1

    estrogen receptor alpha

  • EZH2, enhancer of zeste 2

    PRC2 subunit

  • FACT, facilitates chromatin transcriptionFAK

    focal adhesion kinase

  • FBXL5

    F-box and leucine rich repeat protein 5

  • FGF

    fibroblast growth factor

  • FLNB

    filamin B

  • FOX, Forkhead box (A1, C1, D3

    M1 denote individual proteins)

  • GATA3/4, GATA binding protein (3

    4 denote different proteins)

  • GLI

    glioma-associated oncogene

  • HAT(s)

    histone acetyltransferase(s)

  • hBRM, human paralog of Drosophila Brahma, a.k.a. SMARCA2 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a

    member 2

  • HCC

    hepatocellular carcinoma

  • HDAC(s)

    histone deacetylase(s)

  • HDGF

    hepatoma-derived growth factor

  • HDM(s)

    histone demethylase(s)

  • HGF

    hepatocyte growth factor

  • HH

    hedgehog

  • HIF-1α

    hypoxia inducible factor 1α

  • HIF-2α

    hypoxia inducible factor 2α

  • HOX

    homeobox

  • HMGA1

    High Mobility Group AT-Hook 1

  • HMGB-1

    high mobility group box 1

  • HMT(s)

    histone methyltransferase(s)

  • HNF4α

    hepatocyte nuclear factor 4α

  • HSF1

    heat shock factor 1

  • HSP5A

    heat shock protein 5A

  • IGF

    insulin-like growth factor

  • IRE1

    Inositol-requiring enzyme 1

  • INO80

    INO80 complex ATPase subunit

  • ISWI

    Imitation SWItch

  • JAK

    Janus kinase

  • JMJD2A, Jumonji-C (JmjC) domain-containing protein 2A

    a.k.a. KMD4A

  • JMJD5, Jumonji-C (JmjC) domain-containing protein 5

    a.k.a. KDM8

  • JNK

    c-Jun N-terminal kinase

  • KDM4A

    lysine demethylase 4Aα

  • KDM6A, lysine demethylase 6A

    a.k.a. UTX histone demethylase

  • KDM8

    lysine demethylase 8

  • KLF6

    Krueppel-like factor 6

  • lncRNA

    long non-coding RNA

  • LOXL2

    lysyl oxidase-like 2

  • MET

    mesenchymal-epithelial transition

  • miRNA(s)

    micro RNA(s)

  • MNK1/2

    mitogen-activated protein kinase-interacting kinases 1 and 2

  • MTOR

    mechanistic/mammalian target of rapamycin

  • NC

    neural crest

  • NEUROD1

    neuronal differentiation 1

  • NEUROG1

    neurogenin 1

  • NEUROG 2

    neurogenin 2

  • NFκB

    nuclear factor kappa-light-chain-enhancer of activated B cells

  • NPM1

    nucleophosmin 1

  • NRF2

    nuclear factor erythroid-derived 2-related factor 2

  • NuRD

    nucleosome remodeling and deacetylase

  • NURF

    nucleosome remodeling factor

  • MYOSLID, myocardin-induced smooth muscle lncRNA

    inducer of differentiation

  • MAPK

    mitogen activated protein kinase

  • MMP

    matrix metalloproteinase

  • MRNA

    messenger ribonucleic acid

  • MTA1

    metastasis-associated antigen 1

  • MTA3

    metastasis-associated antigen 3

  • PAF

    PCNA clamp associated factor

  • PCG

    Polycomb group

  • PH

    pleckstrin homology

  • PI3K

    phosphoinositide 3-kinase

  • PIK3CA, phosphatidylinositol-4

    5-bisphosphate 3-kinase catalytic subunit alpha

  • PTEN

    phosphatase and tensin homolog

  • PRC2

    polycomb repressive complex 2

  • RAGE, a.k.a. AGER

    advanced glycosylation end-product specific receptor

  • RNA

    ribonucleic acid

  • SHH

    sonic hedgehog

  • SIRT-1

    Sirtuin 1

  • SOX4

    SRY-box transcription factor 4

  • SSRP1

    structure specific recognition protein 1

  • STAT3

    signal transducer and activator of transcription 3

  • SUPT6H, SPT6 homolog

    histone chaperone and transcription elongation factor

  • SUPT16H, SPT16 homolog

    facilitates chromatin remodeling subunit

  • SWI/SNF

    SWItch/Sucrose Non-Fermentable

  • TAZ

    transcriptional coactivator with PDZ binding motif

  • TF(S)

    transcription factor(s)

  • TGFβ

    transforming growth factor beta

  • TLR4

    Toll-like receptor 4

  • TRIO

    Rho guanine nucleotide exchange factor

  • TRPV4

    transient receptor potential vanilloid 4

  • UNC-40, un-coordinated 40

    a netrin receptor. C. elegans homolog of DCC

  • UPA

    urokinase-type plasminogen activator

  • UTRs

    untranslated regions

  • VEGF(A)

    vascular endothelial growth factor (A)

  • WNT, fusion of the name of the Drosophila segment polarity gene wingless and the name of the vertebrate homolog

    integrated or int-1

  • XBP1

    x-box–binding protein 1

  • YAP

    yes-associated protein

  • ZEB1

    zinc finger E-box binding homeobox 1

  • ZEB2

    zinc finger E-box binding homeobox 2.

References

  • 1.

    KalluriRWeinbergRA. The basics of epithelial-mesenchymal transition. J Clin Invest. (2009) 119:1420–8. 10.1172/JCI39104

  • 2.

    ZeisbergMNeilsonEG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. (2009) 119:1427–37. 10.1172/JCI36183

  • 3.

    BediUMishraVKWasilewskiDScheelCJohnsenSA. Epigenetic plasticity: a central regulator of epithelial-to-mesenchymal transition in cancer. Oncotarget. (2014) 5:2016–29. 10.18632/oncotarget.1875

  • 4.

    ThieryJPAcloqueHHuangRYNietoMA. Epithelial-mesenchymal transitions in development and disease. Cell. (2009) 139:871–90. 10.1016/j.cell.2009.11.007

  • 5.

    YangJDuXWangGSunYChenKZhuXet al. Mesenchymal to epithelial transition in sarcomas. Eur J Cancer. (2014) 50:593–601. 10.1016/j.ejca.2013.11.006

  • 6.

    BanCRTwiggSM. Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers. Vasc Health Risk Manag. (2008) 4:575–96. 10.2147/VHRM.S1991

  • 7.

    PatelSSrivastavaSSinghMRSinghD. Mechanistic insight into diabetic wounds: pathogenesis, molecular targets and treatment strategies to pace wound healing. Biomed Pharmacother. (2019) 112:108615. 10.1016/j.biopha.2019.108615

  • 8.

    TraversJGKamalFARobbinsJYutzeyKEBlaxallBC. Cardiac fibrosis: the fibroblast awakens. Circ Res. (2016) 118:1021–40. 10.1161/CIRCRESAHA.115.306565

  • 9.

    Rout-PittNFarrowNParsonsDDonnelleyM. Epithelial mesenchymal transition (EMT): a universal process in lung diseases with implications for cystic fibrosis pathophysiology. Respir Res. (2018) 19:136. 10.1186/s12931-018-0834-8

  • 10.

    SunLFangJ. Epigenetic regulation of epithelial-mesenchymal transition. Cell Mol Life Sci. (2016) 73:4493–515. 10.1007/s00018-016-2303-1

  • 11.

    LängstGManelyteL. Chromatin remodelers: from function to dysfunction. Genes. (2015) 6:299–324. 10.3390/genes6020299

  • 12.

    KiesslichTPichlerMNeureiterD. Epigenetic control of epithelial-mesenchymal-transition in human cancer. Mol Clin Oncol. (2013) 1:3–11. 10.3892/mco.2012.28

  • 13.

    Serrano-GomezSJMaziveyiMAlahariSK. Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications. Mol Cancer. (2016) 15:18. 10.1186/s12943-016-0502-x

  • 14.

    LachatCBoyer-GuittautMPeixotoPHervouetE. Epigenetic regulation of EMT (epithelial to mesenchymal transition) and tumor aggressiveness: a view on paradoxical roles of KDM6B and EZH2. Epigenomes. (2018) 3:1. 10.3390/epigenomes3010001

  • 15.

    BellOTiwariVKThomaNHSchubelerD. Determinants and dynamics of genome accessibility. Nat Rev Genet. (2011) 12:554–64. 10.1038/nrg3017

  • 16.

    TiwariVKMcGarveyKMLicchesiJDFOhmJEHermanJGSchübelerDet al. PcG proteins, DNA methylation, and gene repression by chromatin looping. PLoS Biol. (2008) 6:2911–27. 10.1371/journal.pbio.0060306

  • 17.

    Llinàs-AriasPEstellerM. Epigenetic inactivation of tumour suppressor coding and non-coding genes in human cancer: an update. Open Biol. (2017) 7:170152. 10.1098/rsob.170152

  • 18.

    XiongMJiangLZhouYQiuWFangLTanRet al. The miR-200 family regulates TGF-beta1-induced renal tubular epithelial to mesenchymal transition through smad pathway by targeting ZEB1 and ZEB2 expression. Am J Physiol Renal Physiol. (2012) 302:F369–79. 10.1152/ajprenal.00268.2011

  • 19.

    DhamijaSDiederichsS. From junk to master regulators of invasion: lncRNA functions in migration, EMT and metastasis. Int J Cancer. (2016) 139:269–80. 10.1002/ijc.30039

  • 20.

    CaoM-XJiangY-PTangY-LLiangX-H. The crosstalk between lncRNA and microRNA in cancer metastasis: orchestrating the epithelial-mesenchymal plasticity. Oncotarget. (2017) 8:12472–83. 10.18632/oncotarget.13957

  • 21.

    DaugaardISandersKJIdicaAVittayarukskulKHamdorfMKrogJDet al. miR-151a induces partial EMT by regulating E-cadherin in NSCLC cells. Oncogenesis. (2017) 6:e366. 10.1038/oncsis.2017.66

  • 22.

    XiongH-GLiHXiaoYYangQ-CYangL-LChenLet al. Long noncoding RNA MYOSLID promotes invasion and metastasis by modulating the partial epithelial-mesenchymal transition program in head and neck squamous cell carcinoma. J Exp Clin Cancer Res. (2019) 38:278. 10.1186/s13046-019-1254-4

  • 23.

    WuWChenFCuiXYangLChenJZhaoJet al. LncRNA NKILA suppresses TGF-β-induced epithelial-mesenchymal transition by blocking NF-κB signaling in breast cancer. Int J Cancer. (2018) 143:2213–24. 10.1002/ijc.31605

  • 24.

    BurgerGADanenEHJBeltmanJB. Deciphering epithelial-mesenchymal transition regulatory networks in cancer through computational approaches. Front Oncol. (2017) 7:162. 10.3389/fonc.2017.00162

  • 25.

    TamWLWeinbergRA. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med. (2013) 19:1438–49. 10.1038/nm.3336

  • 26.

    DamaskosCValsamiSSpartalisEAntoniouEATomosPKaramaroudisSet al. Histone deacetylase inhibitors: a novel therapeutic weapon against medullary thyroid cancer?Anticancer Res. (2016) 36:5019–24. 10.21873/anticanres.11070

  • 27.

    MeadowsKLHurwitzHI. Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med. (2012) 2:a006577. 10.1101/cshperspect.a006577

  • 28.

    TewariKSSillMWLongHJPensonRTHuangHRamondettaLMet al. Improved survival with bevacizumab in advanced cervical cancer. New Eng J Med. (2014) 370:734–43. 10.1056/NEJMoa1309748

  • 29.

    ZirlikKDuysterJ. Anti-angiogenics: current situation and future perspectives. Oncol Res Treat. (2018) 41:166–71. 10.1159/000488087

  • 30.

    MiettinenPJEbnerRLopezARDerynckR. TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J Cell Biol. (1994) 127:2021–36. 10.1083/jcb.127.6.2021

  • 31.

    HugoHAcklandMLBlickTLawrenceMGClementsJAWilliamsEDet al. Epithelial–mesenchymal and mesenchymal–epithelial transitions in carcinoma progression. J Cell Physiol. (2007) 213:374–83. 10.1002/jcp.21223

  • 32.

    CursonsJLeuchowiusK-JWalthamMTomaskovic-CrookEForoutanMBrackenCPet al. Stimulus-dependent differences in signalling regulate epithelial-mesenchymal plasticity and change the effects of drugs in breast cancer cell lines. Cell Commun Signal. (2015) 13:26. 10.1186/s12964-015-0106-x

  • 33.

    IwanoMPleithDDanoffTMXueCOkadaHNeilsonEG. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest. (2002) 110:341–9. 10.1172/JCI0215518

  • 34.

    CañadasITausAGonzálezIVillanuevaXGimenoJPijuanLet al. High circulating hepatocyte growth factor levels associate with epithelial to mesenchymal transition and poor outcome in small cell lung cancer patients. Oncotarget. (2014) 5:5246–56. 10.18632/oncotarget.2124

  • 35.

    SagiZHieronymusT. The impact of the epithelial-mesenchymal transition regulator hepatocyte growth factor receptor/met on skin immunity by modulating langerhans cell migration. Front Immunol. (2018) 9:517. 10.3389/fimmu.2018.00517

  • 36.

    MakPLeavIPursellBBaeDYangXTaglientiCAet al. ERβ impedes prostate cancer EMT by destabilizing HIF-1α and inhibiting VEGF-mediated snail nuclear localization: implications for gleason grading. Cancer Cell. (2010) 17:319–32. 10.1016/j.ccr.2010.02.030

  • 37.

    FantozziAGruberDCPisarskyLHeckCKunitaAYilmazMet al. VEGF-mediated angiogenesis links EMT-induced cancer stemness to tumor initiation. Cancer Res. (2014) 74:1566. 10.1158/0008-5472.CAN-13-1641

  • 38.

    LiCWangQShenSWeiXLiG. HIF-1α/VEGF signaling-mediated epithelial–mesenchymal transition and angiogenesis is critically involved in anti-metastasis effect of luteolin in melanoma cells. Phytother Res. (2019) 33:798–807. 10.1002/ptr.6273

  • 39.

    GrahamTRZhauHEOdero-MarahVAOsunkoyaAOKimbroKSTighiouartMet al. Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res. (2008) 68:2479–88. 10.1158/0008-5472.CAN-07-2559

  • 40.

    LiHBatthISQuXXuLSongNWangRet al. IGF-IR signaling in epithelial to mesenchymal transition and targeting IGF-IR therapy: overview and new insights. Mol Cancer. (2017) 16:6. 10.1186/s12943-016-0576-5

  • 41.

    ZhangJTianX-JXingJ. Signal transduction pathways of EMT induced by TGF-β, SHH, and WNT and their crosstalks. J Clin Med. (2016) 5:41. 10.3390/jcm5040041

  • 42.

    GuptaSTakebeNLorussoP. Targeting the hedgehog pathway in cancer. Ther Adv Med Oncol. (2010) 2:237–50. 10.1177/1758834010366430

  • 43.

    YooYAKangMHLeeHJKimBHParkJKKimHKet al. Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in gastric cancer. Cancer Res. (2011) 71:7061–70. 10.1158/0008-5472.CAN-11-1338

  • 44.

    KatsunoYHanyuAKandaHIshikawaYAkiyamaFIwaseTet al. Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through smad pathway. Oncogene. (2008) 27:6322–33. 10.1038/onc.2008.232

  • 45.

    KangMHKangHNKimJLKimJSOhSCYooYA. Inhibition of PI3 kinase/Akt pathway is required for BMP2-induced EMT and invasion. Oncol Rep. (2009) 22:525–34. 10.3892/or_00000467

  • 46.

    ParkK-SDubonMJGumbinerBM. N-cadherin mediates the migration of MCF-10A cells undergoing bone morphogenetic protein 4-mediated epithelial mesenchymal transition. Tumour Biol. (2015) 36:3549–56. 10.1007/s13277-014-2991-9

  • 47.

    ZabkiewiczCResaulJHargestRJiangWGYeL. Bone morphogenetic proteins, breast cancer, and bone metastases: striking the right balance. Endocr Relat Cancer. (2017) 24:R349–66. 10.1530/ERC-17-0139

  • 48.

    LiC-WXiaWHuoLLimS-OWuYHsuJLet al. Epithelial–mesenchymal transition induced by TNF-α requires NF-κB–mediated transcriptional upregulation of twist1. Cancer Res. (2012) 72:1290–300. 10.1158/0008-5472.CAN-11-3123

  • 49.

    PeixotoPEtcheverryAAubryMMisseyALachatCPerrardJet al. EMT is associated with an epigenetic signature of ECM remodeling genes. Cell Death Dis. (2019) 10:205. 10.1038/s41419-019-1397-4

  • 50.

    van den BeuckenTKochEChuKRupaimooleRPrickaertsPAdriaensMet al. Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. Nat Commun. (2014) 5:5203. 10.1038/ncomms6203

  • 51.

    SharmaTRadosevichJAPachoriGMandalCC. A molecular view of pathological microcalcification in breast cancer. J Mammary Gland Biol Neoplasia. (2016) 21:25–40. 10.1007/s10911-015-9349-9

  • 52.

    WilkinsonLThomasVSharmaN. Microcalcification on mammography: approaches to interpretation and biopsy. Br J Radiol. (2017) 90:20160594. 10.1259/bjr.20160594

  • 53.

    ConventoMBPessoaEACruzEdaGlória MASchorNBorgesFT. Calcium oxalate crystals and oxalate induce an epithelial-to-mesenchymal transition in the proximal tubular epithelial cells: contribution to oxalate kidney injury. Sci Rep. (2017) 7:45740. 10.1038/srep45740

  • 54.

    ConventoMPessoaEAragãoASchorNBorgesF. Oxalate induces type II epithelial to mesenchymal transition (EMT) in inner medullary collecting duct cells (IMCD) in vitro and stimulate the expression of osteogenic and fibrotic markers in kidney medulla in vivo. Oncotarget. (2019) 10:1102–18. 10.18632/oncotarget.26634

  • 55.

    CastellaroAMTondaACejasHHFerreyraHCaputtoBLPucciOAet al. Oxalate induces breast cancer. BMC Cancer. (2015) 15:761. 10.1186/s12885-015-1747-2

  • 56.

    PeerapenPThongboonkerdV. p38 MAPK mediates calcium oxalate crystal-induced tight junction disruption in distal renal tubular epithelial cells. Sci Rep. (2013) 3:1041. 10.1038/srep01041

  • 57.

    KanlayaRKhamchunSKapincharanonCThongboonkerdV. Protective effect of epigallocatechin-3-gallate (EGCG) via Nrf2 pathway against oxalate-induced epithelial mesenchymal transition (EMT) of renal tubular cells. Sci Rep. (2016) 6:30233. 10.1038/srep30233

  • 58.

    OyanadelCHolmesCPardoERetamalCShaughnessyRSmithPet al. Galectin-8 induces partial epithelial-mesenchymal transition with invasive tumorigenic capabilities involving a FAK/EGFR/proteasome pathway in madin-darby canine kidney cells. Mol Biol Cell. (2018) 29:557–74. 10.1091/mbc.E16-05-0301

  • 59.

    LeeWHChoongLYJinTHMonNNChongSLiewCSet al. TRPV4 plays a role in breast cancer cell migration via Ca(2+)-dependent activation of AKT and downregulation of E-cadherin cell cortex protein. Oncogenesis. (2017) 6:e338. 10.1038/oncsis.2017.39

  • 60.

    NalluriSMO'ConnorJWGomezEW. Cytoskeletal signaling in TGFbeta-induced epithelial-mesenchymal transition. Cytoskeleton. (2015) 72:557–69. 10.1002/cm.21263

  • 61.

    ShahPPFongMYKakarSS. PTTG induces EMT through integrin αVβ3-focal adhesion kinase signaling in lung cancer cells. Oncogene. (2012) 31:3124–35. 10.1038/onc.2011.488

  • 62.

    ChaturvediVFournier-LevelACooperHMMurrayMJ. Loss of neogenin1 in human colorectal carcinoma cells causes a partial EMT and wound-healing response. Sci Rep. (2019) 9:4110. 10.1038/s41598-019-40886-y

  • 63.

    FanL-CTengH-WShiauC-WTaiW-THungM-HYangS-Het al. Regorafenib (stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer. Oncotarget. (2016) 7:64136–47. 10.18632/oncotarget.11636

  • 64.

    AwasthiNMikels-VigdalAJStefanuttiESchwarzMAMonahanSSmithVet al. Therapeutic efficacy of anti-MMP9 antibody in combination with nab-paclitaxel-based chemotherapy in pre-clinical models of pancreatic cancer. J Cell Mol Med. (2019) 23:3878–87. 10.1111/jcmm.14242

  • 65.

    OwyongMChouJvan den BijgaartRJKongNEfeGMaynardCet al. MMP9 modulates the metastatic cascade and immune landscape for breast cancer anti-metastatic therapy. Life Sci Alliance. (2019) 2:e201800226. 10.26508/lsa.201800226

  • 66.

    TanakaHKonoETranCPMiyazakiHYamashiroJShimomuraTet al. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med. (2010) 16:1414–20. 10.1038/nm.2236

  • 67.

    DaiJHeHLinDWangCZhuYXuD. Up-regulation of E-cadherin by saRNA inhibits the migration and invasion of renal carcinoma cells. Int J Clin Exp Pathol. (2018) 11:5792–800.

  • 68.

    PadmanabanVKrolISuhailYSzczerbaBMAcetoNBaderJSet al. E-cadherin is required for metastasis in multiple models of breast cancer. Nature. (2019) 573:439–44. 10.1038/s41586-019-1526-3

  • 69.

    ChamesPVan RegenmortelMWeissEBatyD. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. (2009) 157:220–33. 10.1111/j.1476-5381.2009.00190.x

  • 70.

    HannaJHossainGSKocerhaJ. The potential for microRNA therapeutics and clinical research. Front Genet. (2019) 10:478. 10.3389/fgene.2019.00478

  • 71.

    MeiMRenYZhouXYuanXBHanLWangGXet al. Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells. Technol Cancer Res Treat. (2010) 9:77–86. 10.1177/153303461000900109

  • 72.

    Van RoosbroeckKFaniniFSetoyamaTIvanCRodriguez-AguayoCFuentes-MatteiEet al. Combining Anti-Mir-155 with chemotherapy for the treatment of lung cancers. Clin Cancer Res. (2017) 23:2891. 10.1158/1078-0432.CCR-16-1025

  • 73.

    BarnehFMirzaieMNickchiPTanTZThieryJPPiranMet al. Integrated use of bioinformatic resources reveals that co-targeting of histone deacetylases, IKBK and SRC inhibits epithelial-mesenchymal transition in cancer. Brief Bioinform. (2018) 20:717–31. 10.1093/bib/bby030

  • 74.

    BrabletzT. To differentiate or not—routes towards metastasis. Nat Rev Cancer. (2012) 12:425–36. 10.1038/nrc3265

  • 75.

    PattabiramanDRWeinbergRA. Tackling the cancer stem cells—what challenges do they pose?Nat Rev Drug Discov. (2014) 13:497–512. 10.1038/nrd4253

  • 76.

    Ishay-RonenDDiepenbruckMKalathurRKRSugiyamaNTiedeSIvanekRet al. Gain fat - lose metastasis: converting invasive breast cancer cells into adipocytes inhibits cancer metastasis. Cancer Cell. (2019) 35:17–32.e16. 10.1016/j.ccell.2018.12.002

  • 77.

    HseuY-CLinY-CRajendranPThigarajanVMathewDCLinK-Yet al. Antrodia salmonea suppresses invasion and metastasis in triple-negative breast cancer cells by reversing EMT through the NF-κB and Wnt/β-catenin signaling pathway. Food Chem Toxicol. (2019) 124:219–30. 10.1016/j.fct.2018.12.009

  • 78.

    MorozECarlinSDyominaKBurkeSThalerHTBlasbergRet al. Real-time imaging of HIF-1alpha stabilization and degradation. PLoS ONE. (2009) 4:e5077. 10.1371/journal.pone.0005077

  • 79.

    HannaCHubchakSCLiangXRozen-ZviBSchumackerPTHayashidaTet al. Hypoxia-inducible factor-2α and TGF-β signaling interact to promote normoxic glomerular fibrogenesis. Am J Physiol Renal Physiol. (2013) 305:F1323. 10.1152/ajprenal.00155.2013

  • 80.

    XieMZhangLHeCSXuFLiuJLHuZHet al. Activation of notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells. J Cell Biochem. (2012) 113:1501–13. 10.1002/jcb.24019

  • 81.

    IshidaTHijiokaHKumeKMiyawakiANakamuraN. Notch signaling induces EMT in OSCC cell lines in a hypoxic environment. Oncol Lett. (2013) 6:1201–6. 10.3892/ol.2013.1549

  • 82.

    LamouilleSXuJDerynckR. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. (2014) 15:178–96. 10.1038/nrm3758

  • 83.

    XuWYangZLuN. A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition. Cell Adh Migr. (2015) 9:317–24. 10.1080/19336918.2015.1016686

  • 84.

    LiuXLiZSongYWangRHanLWangQet al. AURKA induces EMT by regulating histone modification through Wnt/β-catenin and PI3K/Akt signaling pathway in gastric cancer. Oncotarget. (2016) 7:33152–64. 10.18632/oncotarget.8888

  • 85.

    QinHLiuXLiFMiaoLLiTXuBet al. PAD1 promotes epithelial-mesenchymal transition and metastasis in triple-negative breast cancer cells by regulating MEK1-ERK1/2-MMP2 signaling. Cancer Lett. (2017) 409:30–41. 10.1016/j.canlet.2017.08.019

  • 86.

    JulienSPuigICarettiEBonaventureJNellesLvan RoyFet al. Activation of NF-kappaB by Akt upregulates Snail expression and induces epithelium mesenchyme transition. Oncogene. (2007) 26:7445–56. 10.1038/sj.onc.1210546

  • 87.

    NavandarMGardingASahuSKPataskarASchickSTiwariVK. ERK signalling modulates epigenome to drive epithelial to mesenchymal transition. Oncotarget. (2017) 8:29269–81. 10.18632/oncotarget.16493

  • 88.

    ChenJZhuHLiuQNingDZhangZZhangLet al. DEPTOR induces a partial epithelial-to-mesenchymal transition and metastasis via autocrine TGFβ1 signaling and is associated with poor prognosis in hepatocellular carcinoma. J Exp Clin Cancer Res. (2019) 38:273. 10.1186/s13046-019-1220-1

  • 89.

    ParkJKimD-HShahSRKimH-NKshitizKimPet al. Switch-like enhancement of epithelial-mesenchymal transition by YAP through feedback regulation of WT1 and Rho-family GTPases. Nat Commun. (2019) 10:2797. 10.1038/s41467-019-10729-5

  • 90.

    McFaline-FigueroaJLHillAJQiuXJacksonDShendureJTrapnellC. A pooled single-cell genetic screen identifies regulatory checkpoints in the continuum of the epithelial-to-mesenchymal transition. Nat Genet. (2019) 51:1389–98. 10.1038/s41588-019-0489-5

  • 91.

    SahuSKGardingATiwariNThakurelaSToedlingJGebhardSet al. JNK-dependent gene regulatory circuitry governs mesenchymal fate. EMBO J. (2015) 34:2162–81. 10.15252/embj.201490693

  • 92.

    WojciechowskiMCMahmutovicLShuDYLovicuFJ. ERK1/2 signaling is required for the initiation but not progression of TGFβ-induced lens epithelial to mesenchymal transition (EMT). Exp Eye Res. (2017) 159:98–113. 10.1016/j.exer.2017.03.012

  • 93.

    WuYXuXMaLYiQSunWTangL. Calreticulin regulates TGF-β1-induced epithelial mesenchymal transition through modulating smad signaling and calcium signaling. Int J Biochem Cell Biol. (2017) 90:103–13. 10.1016/j.biocel.2017.07.023

  • 94.

    Zemljic-HarpfAMansoAMRossRS. Vinculin and talin: focus on the myocardium. J Investig Med. (2009) 57:849–55. 10.2310/JIM.0b013e3181c5e074

  • 95.

    WuJHeZYangXMLiKLWangDLSunFL. RCCD1 depletion attenuates TGF-β-induced EMT and cell migration by stabilizing cytoskeletal microtubules in NSCLC cells. Cancer Lett. (2017) 400:18–29. 10.1016/j.canlet.2017.04.021

  • 96.

    GladilinEOhseSBoerriesMBuschHXuCSchneiderMet al. TGFβ-induced cytoskeletal remodeling mediates elevation of cell stiffness and invasiveness in NSCLC. Sci Rep. (2019) 9:7667. 10.1038/s41598-019-43409-x

  • 97.

    RamamurthyVPRamalingamSGediyaLKNjarVCO. The retinamide VNLG-152 inhibits f-AR/AR-V7 and MNK-eIF4E signaling pathways to suppress EMT and castration-resistant prostate cancer xenograft growth. FEBS J. (2018) 285:1051–63. 10.1111/febs.14383

  • 98.

    CuevasEPErasoPMazónMJSantosVMoreno-BuenoGCanoAet al. LOXL2 drives epithelial-mesenchymal transition via activation of IRE1-XBP1 signalling pathway. Sci Rep. (2017) 7:44988. 10.1038/srep44988

  • 99.

    XiongYSunFDongPWatariHYueJYuM-Fet al. iASPP induces EMT and cisplatin resistance in human cervical cancer through miR-20a-FBXL5/BTG3 signaling. J Exp Clin Cancer Res. (2017) 36:48. 10.1186/s13046-017-0520-6

  • 100.

    WuWDingHCaoJZhangW. FBXL5 inhibits metastasis of gastric cancer through suppressing snail1. Cell Physiol Biochem. (2015) 35:1764–72. 10.1159/000373988

  • 101.

    YaoHSuSXiaDWangMLiZChenWet al. F-box and leucine-rich repeat protein 5 promotes colon cancer progression by modulating PTEN/PI3K/AKT signaling pathway. Biomed Pharmacother. (2018) 107:1712–9. 10.1016/j.biopha.2018.08.119

  • 102.

    SahuSKTiwariNPataskarAZhuangYBorisovaMDikenMet al. FBXO32 promotes microenvironment underlying epithelial-mesenchymal transition via CtBP1 during tumour metastasis and brain development. Nat Commun. (2017) 8:1523. 10.1038/s41467-017-01366-x

  • 103.

    KaracostaLGAnchangBIgnatiadisNKimmeySCBensonJAShragerJBet al. Mapping lung cancer epithelial-mesenchymal transition states and trajectories with single-cell resolution. Nat Commun. (2019) 10:5587. 10.1038/s41467-019-13441-6

  • 104.

    GrasBJacqueroudLWierinckxALamblotCFauvetFLachuerJet al. Snail Family members unequally trigger EMT and thereby differ in their ability to promote the neoplastic transformation of mammary epithelial cells. PLoS ONE. (2014) 9:e92254. 10.1371/journal.pone.0092254

  • 105.

    Meyer-SchallerNCardnerMDiepenbruckMSaxenaMTiedeSLüöndFet al. A hierarchical regulatory landscape during the multiple stages of EMT. Dev Cell. (2019) 48:539–53.e536. 10.1016/j.devcel.2018.12.023

  • 106.

    BocciFTripathiSCVilchez MercedesSAGeorgeJTCasabarJPWongPKet al. NRF2 activates a partial epithelial-mesenchymal transition and is maximally present in a hybrid epithelial/mesenchymal phenotype. Integr Biol. (2019) 11:251–63. 10.1093/intbio/zyz021

  • 107.

    Iwafuchi-DoiMZaretKS. Pioneer transcription factors in cell reprogramming. Genes Dev. (2014) 28:2679–92. 10.1101/gad.253443.114

  • 108.

    PataskarAJungJSmialowskiPNoackFCalegariFStraubTet al. NeuroD1 reprograms chromatin and transcription factor landscapes to induce the neuronal program. EMBO J. (2016) 35:24–45. 10.15252/embj.201591206

  • 109.

    ManavathiBSamanthapudiVSKGajulapalliVNR. Estrogen receptor coregulators and pioneer factors: the orchestrators of mammary gland cell fate and development. Front Cell Dev Bio. (2014) 2:34. 10.3389/fcell.2014.00034

  • 110.

    GuoRTangWYuanQHuiLWangXXieX. Chemical cocktails enable hepatic reprogramming of mouse fibroblasts with a single transcription factor. Stem Cell Rep. (2017) 9:499–512. 10.1016/j.stemcr.2017.06.013

  • 111.

    LiJSongPJiangTDaiDWangHSunJet al. Heat shock factor 1 epigenetically stimulates glutaminase-1-dependent mTOR activation to promote colorectal carcinogenesis. Mol Ther. (2018) 26:1828–39. 10.1016/j.ymthe.2018.04.014

  • 112.

    SkrypekNBruneelKVandewalleCDe SmedtESoenBLoretNet al. ZEB2 stably represses RAB25 expression through epigenetic regulation by SIRT1 and DNMTs during epithelial-to-mesenchymal transition. Epigenetics Chromatin. (2018) 11:70. 10.1186/s13072-018-0239-4

  • 113.

    Simões-CostaMBronnerME. Establishing neural crest identity: a gene regulatory recipe. Development. (2015) 142:242–57. 10.1242/dev.105445

  • 114.

    LukoseviciuteMGavriouchkinaDWilliamsRMHochgreb-HageleTSenanayakeUChong-MorrisonVet al. From pioneer to repressor: bimodal foxd3 activity dynamically remodels neural crest regulatory landscape in vivo. Dev Cell. (2018) 47:608–28.e606. 10.1016/j.devcel.2018.11.009

  • 115.

    LiHIlinSWangWDuncanEMWysockaJAllisCDet al. Molecular basis for site-specific read-out of histone H3K4me3 by the BPTF PHD finger of NURF. Nature. (2006) 442:91–5. 10.1038/nature04802

  • 116.

    XiaoSLiuLFangMZhouXPengXLongJet al. BPTF associated with EMT indicates negative prognosis in patients with hepatocellular carcinoma. Dig Dis Sci. (2015) 60:910–8. 10.1007/s10620-014-3411-0

  • 117.

    ZhangJLiangQLeiYYaoMLiLGaoXet al. SOX4 induces epithelial-mesenchymal transition and contributes to breast cancer progression. Cancer Res. (2012) 72:4597–608. 10.1158/0008-5472.CAN-12-1045

  • 118.

    TiwariNTiwariVKWaldmeierLBalwierzPJArnoldPPachkovMet al. Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming. Cancer Cell. (2013) 23:768–83. 10.1016/j.ccr.2013.04.020

  • 119.

    WangJHeCGaoPWangSLvRZhouHet al. HNF1B-mediated repression of SLUG is suppressed by EZH2 in aggressive prostate cancer. Oncogene. (2019) 39:1335–46. 10.1038/s41388-019-1065-2

  • 120.

    XieSLFanSZhangSYChenWXLiQXPanGKet al. SOX8 regulates cancer stem-like properties and cisplatin-induced EMT in tongue squamous cell carcinoma by acting on the Wnt/β-catenin pathway. Int J Cancer. (2018) 142:1252–65. 10.1002/ijc.31134

  • 121.

    KrivtsovaOMakarovaALazarevichN. Aberrant expression of alternative isoforms of transcription factors in hepatocellular carcinoma. World J Hepatol. (2018) 10:645–61. 10.4254/wjh.v10.i10.645

  • 122.

    LazarevichNLCheremnovaOAVargaEVOvchinnikovDAKudrjavtsevaEIMorozovaOVet al. Progression of HCC in mice is associated with a downregulation in the expression of hepatocyte nuclear factors. Hepatology. (2004) 39:1038–47. 10.1002/hep.20155

  • 123.

    VuongLMChellappaKDhahbiJMDeansJRFangBBolotinEet al. Differential effects of hepatocyte nuclear factor 4α isoforms on tumor growth and t-cell factor 4/AP-1 interactions in human colorectal cancer cells. Mol Cell Biol. (2015) 35:3471–90. 10.1128/MCB.00030-15

  • 124.

    LiJChoiPSChafferCLLabellaKHwangJHGiacomelliAOet al. An alternative splicing switch in FLNB promotes the mesenchymal cell state in human breast cancer. Elife. (2018) 7:e37184. 10.7554/eLife.37184

  • 125.

    SabolMTrnskiDMusaniVOzretićPLevanatS. Role of GLI transcription factors in pathogenesis and their potential as new therapeutic targets. Int J Mol Sci. (2018) 19:2562. 10.3390/ijms19092562

  • 126.

    FuJRodovaMRoySKSharmaJSinghKPSrivastavaRKet al. GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft. Cancer Lett. (2013) 330:22–32. 10.1016/j.canlet.2012.11.018

  • 127.

    ZaninRPegoraroSRosGCianiYPiazzaSBossiFet al. HMGA1 promotes breast cancer angiogenesis supporting the stability, nuclear localization and transcriptional activity of FOXM1. J Exp Clin Cancer Res. (2019) 38:313. 10.1186/s13046-019-1307-8

  • 128.

    PoliVFagnocchiLFascianiACherubiniAMazzoleniSFerrilloSet al. MYC-driven epigenetic reprogramming favors the onset of tumorigenesis by inducing a stem cell-like state. Nat Commun. (2018) 9:1024. 10.1038/s41467-018-03264-2

  • 129.

    WidomJ. Structure, dynamics, and function of chromatin in vitro. Annu Rev Biophys Biomol Struct. (1998) 27:285–327. 10.1146/annurev.biophys.27.1.285

  • 130.

    MercerTRMattickJS. Structure and function of long noncoding RNAs in epigenetic regulation. Nat Struct Mol Biol. (2013) 20:300–7. 10.1038/nsmb.2480

  • 131.

    KagamiYYoshidaK. The functional role for condensin in the regulation of chromosomal organization during the cell cycle. Cell Mol Life Sci. (2016) 73:4591–8. 10.1007/s00018-016-2305-z

  • 132.

    TeifVBBohincK. Condensed DNA: condensing the concepts. Prog Biophys Mol Biol. (2011) 105:208–22. 10.1016/j.pbiomolbio.2010.07.002

  • 133.

    RaviMRamanathanSKrishnaK. Factors, mechanisms and implications of chromatin condensation and chromosomal structural maintenance through the cell cycle. J Cell Physiol. (2019) 235:758–75. 10.1002/jcp.29038

  • 134.

    BiswasSMallikarjuna RaoC. Epigenetic tools (the writers, the readers and the rasers) and their implications in cancer therapy. Eur J Pharmacol. (2018) 837:8–24. 10.1016/j.ejphar.2018.08.021

  • 135.

    SeligsonDBHorvathSShiTYuHTzeSGrunsteinMet al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature. (2005) 435:1262–6. 10.1038/nature03672

  • 136.

    Stott-MillerMZhaoSWrightJLKolbSBibikovaMKlotzleBet al. Validation study of genes with hypermethylated promoter regions associated with prostate cancer recurrence. Cancer Epidemiol Biomarkers Prev. (2014) 23:1331–9. 10.1158/1055-9965.EPI-13-10000

  • 137.

    TerryMBMcDonaldJAWuHCEngSSantellaRM. Epigenetic biomarkers of breast cancer risk: across the breast cancer prevention continuum. Adv Exp Med Biol. (2016) 882:33–68. 10.1007/978-3-319-22909-6_2

  • 138.

    SchutteMOgilvieLARiekeDTLangeBMHYaspoMLLehrachH. Cancer precision medicine: why more is more and DNA is not enough. Public Health Genomics. (2017) 20:70–80. 10.1159/000477157

  • 139.

    SoldatovRKauckaMKastritiMEPetersenJChontorotzeaTEnglmaierLet al. Spatiotemporal structure of cell fate decisions in murine neural crest. Science. (2019) 364:eaas9536. 10.1126/science.aas9536

  • 140.

    PowellDRO'BrienJHFordHLArtingerKB. Chapter 16 - neural crest cells and cancer: insights into tumor progression. In: TrainorPA editor. Neural Crest Cells. Boston: Academic Press (2014). p. 335–57.

  • 141.

    VicentGPBallareCNachtASClausellJSubtil-RodriguezAQuilesIet al. Induction of progesterone target genes requires activation of Erk and Msk kinases and phosphorylation of histone H3. Mol Cell. (2006) 24:367–81. 10.1016/j.molcel.2006.10.011

  • 142.

    ZhuPZhangC-BYangPChenJLiuY-QHuH-Met al. Phosphohistone H3 (pHH3) is a prognostic and epithelial to mesenchymal transition marker in diffuse gliomas. Oncotarget. (2016) 7:45005–14. 10.18632/oncotarget.7154

  • 143.

    JuJChenADengYLiuMWangYWangYet al. NatD promotes lung cancer progression by preventing histone H4 serine phosphorylation to activate slug expression. Nat Commun. (2017) 8:928. 10.1038/s41467-017-00988-5

  • 144.

    KalbRMalleryDLLarkinCHuangJTJHiomK. BRCA1 is a histone-H2A-specific ubiquitin ligase. Cell Rep. (2014) 8:999–1005. 10.1016/j.celrep.2014.07.025

  • 145.

    BenitzSRegelIReinhardTPoppASchäfferIRaulefsSet al. Polycomb repressor complex 1 promotes gene silencing through H2AK119 mono-ubiquitination in acinar-to-ductal metaplasia and pancreatic cancer cells. Oncotarget. (2015) 7:11424–33. 10.18632/oncotarget.6717

  • 146.

    JeussetLMPMcManusKJ. Developing targeted therapies that exploit aberrant histone ubiquitination in cancer. Cells. (2019) 8:165. 10.3390/cells8020165

  • 147.

    StadlerSCVincentCTFedorovVDPatsialouACherringtonBDWakshlagJJet al. Dysregulation of PAD4-mediated citrullination of nuclear GSK3β activates TGF-β signaling and induces epithelial-to-mesenchymal transition in breast cancer cells. Proc Natl Acad Sci USA. (2013) 110:11851–6. 10.1073/pnas.1308362110

  • 148.

    DeVoreSBYoungCHLiGSundararajanARamarajTMudgeJet al. Histone citrullination represses MicroRNA expression, resulting in increased oncogene mRNAs in somatolactotrope cells. Mol Cell Biol. (2018) 38:e00084. 10.1128/MCB.00084-18

  • 149.

    GrilzEMauracherLMPoschFKonigsbruggeOZochbauer-MullerSMarosiCet al. Citrullinated histone H3, a biomarker for neutrophil extracellular trap formation, predicts the risk of mortality in patients with cancer. Br J Haematol. (2019) 186:311–20. 10.1055/s-0039-1680128

  • 150.

    ShiioYEisenmanRN. Histone sumoylation is associated with transcriptional repression. Proc Natl Acad Sci USA. (2003) 100:13225–30. 10.1073/pnas.1735528100

  • 151.

    Bawa-KhalfeTLuL-SZuoYHuangCDereRLinF-Met al. Differential expression of SUMO-specific protease 7 variants regulates epithelial-mesenchymal transition. Proc Natl Acad Sci USA. (2012) 109:17466–71. 10.1073/pnas.1209378109

  • 152.

    DhallAWellerCEChuASheltonPMMChatterjeeC. Chemically sumoylated histone H4 stimulates intranucleosomal demethylation by the LSD1-CoREST complex. ACS Chem Biol. (2017) 12:2275–80. 10.1021/acschembio.7b00716

  • 153.

    SoAKCKaurJKakIAssiJMacMillanCRalhanRet al. Biotinidase is a novel marker for papillary thyroid cancer aggressiveness. PLoS ONE. (2012) 7:e40956. 10.1371/journal.pone.0040956

  • 154.

    Jaguva VasudevanAAHoffmannMJBeckMLCPoschmannGPetzschPWiekCet al. HDAC5 expression in urothelial carcinoma cell lines inhibits long-term proliferation but can promote epithelial-to-mesenchymal transition. Int J Mol Sci. (2019) 20:E2135. 10.3390/ijms20092135

  • 155.

    DhayalanARajaveluARathertPTamasRJurkowskaRZRagozinSet al. The Dnmt3a PWWP domain reads histone 3 lysine 36 trimethylation and guides DNA methylation. J Biol Chem. (2010) 285:26114–20. 10.1074/jbc.M109.089433

  • 156.

    CollinsRENorthropJPHortonJRLeeDYZhangXStallcupMRet al. The ankyrin repeats of G9a and GLP histone methyltransferases are mono- and dimethyllysine binding modules. Nat Struct Mol Biol. (2008) 15:245–50. 10.1038/nsmb.1384

  • 157.

    HuangYFangJBedfordMTZhangYXuRM. Recognition of histone H3 lysine-4 methylation by the double tudor domain of JMJD2A. Science. (2006) 312:748–51. 10.1126/science.1125162

  • 158.

    HeynPLoganCVFluteauAChallisRCAuchynnikavaTMartinC-Aet al. Gain-of-function DNMT3A mutations cause microcephalic dwarfism and hypermethylation of Polycomb-regulated regions. Nat Genet. (2019) 51:96–105. 10.1038/s41588-018-0274-x

  • 159.

    ChenL-YHuangY-CHuangS-THsiehY-CGuanH-HChenN-Cet al. Domain swapping and SMYD1 interactions with the PWWP domain of human hepatoma-derived growth factor. Sci Rep. (2018) 8:287. 10.1038/s41598-017-18510-8

  • 160.

    DongCWuYYaoJWangYYuYRychahouPGet al. G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer. J Clin Invest. (2012) 122:1469–86. 10.1172/JCI57349

  • 161.

    CascielloFWindlochKGannonFLeeJS. Functional role of G9a histone methyltransferase in cancer. Front Immunol. (2015) 6:487. 10.3389/fimmu.2015.00487

  • 162.

    MatiasPMBaekSHBandeirasTMDuttaAHouryWALlorcaOet al. The AAA+ proteins pontin and reptin enter adult age: from understanding their basic biology to the identification of selective inhibitors. Front Mol Biosci. (2015) 2:17. 10.3389/fmolb.2015.00017

  • 163.

    ZhangTTermanisAÖzkanBBaoXXCulleyJde Lima AlvesFet al. G9a/GLP complex maintains imprinted DNA methylation in embryonic stem cells. Cell Rep. (2016) 15:77–85. 10.1016/j.celrep.2016.03.007

  • 164.

    LiuNZhangZWuHJiangYMengLXiongJet al. Recognition of H3K9 methylation by GLP is required for efficient establishment of H3K9 methylation, rapid target gene repression, and mouse viability. Genes Dev. (2015) 29:379–93. 10.1101/gad.254425.114

  • 165.

    MaugerOKlinckRChabotBMuchardtCAllemandEBatscheE. Alternative splicing regulates the expression of G9A and SUV39H2 methyltransferases, and dramatically changes SUV39H2 functions. Nucleic Acids Res. (2015) 43:1869–82. 10.1093/nar/gkv013

  • 166.

    PatounasOPapacharalampousIEckerichCMarkopoulosGSKolettasEFackelmayerFO. A novel splicing isoform of protein arginine methyltransferase 1 (PRMT1) that lacks the dimerization arm and correlates with cellular malignancy. J Cell Biochem. (2018) 119:2110–23. 10.1002/jcb.26373

  • 167.

    JiangHZhouZJinSXuKZhangHXuJet al. PRMT9 promotes hepatocellular carcinoma invasion and metastasis via activating PI3K/Akt/GSK-3beta/Snail signaling. Cancer Sci. (2018) 109:1414–27. 10.1111/cas.13598

  • 168.

    Beltrán-GarcíaJOsca-VerdegalRMena-MolláSGarcía-GiménezJL. Epigenetic IVD tests for personalized precision medicine in cancer. Front Genet. (2019) 10:621. 10.3389/fgene.2019.00621

  • 169.

    OzboyaciMGursoyAErmanBKeskinO. Molecular recognition of H3/H4 histone tails by the tudor domains of JMJD2A: a comparative molecular dynamics simulations study. PLoS ONE. (2011) 6:e14765. 10.1371/journal.pone.0014765

  • 170.

    YangW-SCampbellMChangP-C. SUMO modification of a heterochromatin histone demethylase JMJD2A enables viral gene transactivation and viral replication. PLoS Pathog. (2017) 13:e1006216. 10.1371/journal.ppat.1006216

  • 171.

    GinjalaVRodriguez-ColonLGangulyBGangidiPGallinaPAl-HraishawiHet al. Protein-lysine methyltransferases G9a and GLP1 promote responses to DNA damage. Sci Rep. (2017) 7:16613. 10.1038/s41598-017-16480-5

  • 172.

    ChenWZhuQLiuYZhangQ. Chapter nine - chromatin remodeling and plant immunity. In: DonevR editor. Advances in Protein Chemistry and Structural Biology. Swansea: Academic Press (2017). p. 243–60.

  • 173.

    TyagiMImamNVermaKPatelAK. Chromatin remodelers: we are the drivers!!Nucleus. (2016) 7:388–404. 10.1080/19491034.2016.1211217

  • 174.

    WarnsJADavieJRDhasarathyA. Connecting the dots: chromatin and alternative splicing in EMT. Biochem Cell Biol. (2016) 94:12–25. 10.1139/bcb-2015-0053

  • 175.

    Marquez-VilendrerSBRaiSKGramlingSJLuLReismanDN. Loss of the SWI/SNF ATPase subunits BRM and BRG1 drives lung cancer development. Oncoscience. (2016) 3:322–36. 10.18632/oncoscience.323

  • 176.

    WilsonMRReskeJJHolladayJWilberGERhodesMKoemanJet al. ARID1A and PI3-kinase pathway mutations in the endometrium drive epithelial transdifferentiation and collective invasion. Nat Commun. (2019) 10:3554. 10.1038/s41467-019-11403-6

  • 177.

    NagarajanSRaoSVSuttonJCheesemanDDunnSPapachristouEKet al. ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response. Nat Genet. (2020) 52:187–97. 10.1038/s41588-019-0541-5

  • 178.

    BoxJKPaquetNAdamsMNBoucherDBoldersonEO'ByrneKJet al. Nucleophosmin: from structure and function to disease development. BMC Mol Biol. (2016) 17:19. 10.1186/s12867-016-0073-9

  • 179.

    LiuYZhangFZhangX-FQiL-SYangLGuoHet al. Expression of nucleophosmin/NPM1 correlates with migration and invasiveness of colon cancer cells. J Biomed Sci. (2012) 19:53. 10.1186/1423-0127-19-53

  • 180.

    KaowinnSKimJLeeJShinDHKangC-DKimD-Ket al. Cancer upregulated gene 2 induces epithelial-mesenchymal transition of human lung cancer cells via TGF-β signaling. Oncotarget. (2017) 8:5092–110. 10.18632/oncotarget.13867

  • 181.

    LinJKatoMNagataKOkuwakiM. Efficient DNA binding of NF-κB requires the chaperone-like function of NPM1. Nucleic Acids Res. (2017) 45:3707–23. 10.1093/nar/gkw1285

  • 182.

    FormosaT. The role of FACT in making and breaking nucleosomes. Biochim Biophys Acta. (2012) 1819:247–55. 10.1016/j.bbagrm.2011.07.009

  • 183.

    KomanIECommaneMPaszkiewiczGHoonjanBPalSSafinaAet al. Targeting FACT complex suppresses mammary tumorigenesis in Her2/neu transgenic mice. Cancer Prev Res. (2012) 5:1025–35. 10.1158/1940-6207.CAPR-11-0529

  • 184.

    KembleDJWhitbyFGRobinsonHMcCulloughLLFormosaTHillCP. Structure of the Spt16 middle domain reveals functional features of the histone chaperone FACT. J Biol Chem. (2013) 288:10188–94. 10.1074/jbc.C113.451369

  • 185.

    ZhangWZengFLiuYShaoCLiSLvHet al. Crystal structure of human SSRP1 middle domain reveals a role in DNA binding. Sci Rep. (2015) 5:18688. 10.1038/srep18688

  • 186.

    MarcianòGDa VelaSTriaGSvergunDIByronOHuangDT. Structure specific recognition protein-1 (SSRP1) is an elongated homodimer that binds histones. J Biol Chem. (2018) 293:10071–83. 10.1074/jbc.RA117.000994

  • 187.

    WuWHeKGuoQChenJZhangMHuangKet al. SSRP1 promotes colorectal cancer progression and is negatively regulated by miR-28-5p. J Cell Mol Med. (2019) 23:3118–29. 10.1111/jcmm.14134

  • 188.

    BediUScheelAHHennionMBegus-NahrmannYRuschoffJJohnsenSA. SUPT6H controls estrogen receptor activity and cellular differentiation by multiple epigenomic mechanisms. Oncogene. (2015) 34:465–73. 10.1038/onc.2013.558

  • 189.

    WangAHZareHMousaviKWangCMoravecCESirotkinHIet al. The histone chaperone Spt6 coordinates histone H3K27 demethylation and myogenesis. EMBO J. (2013) 32:1075–86. 10.1038/emboj.2013.54

  • 190.

    ChoiH-JParkJ-HParkMWonH-YJooH-SLeeCHet al. UTX inhibits EMT-induced breast CSC properties by epigenetic repression of EMT genes in cooperation with LSD1 and HDAC1. EMBO Rep. (2015) 16:1288–98. 10.15252/embr.201540244

  • 191.

    KuoKTHuangWCBamoduOALeeWHWangCHHsiaoMet al. Histone demethylase JARID1B/KDM5B promotes aggressiveness of non-small cell lung cancer and serves as a good prognostic predictor. Clin Epigenetics. (2018) 10:107. 10.1186/s13148-018-0533-9

  • 192.

    KangRChenRZhangQHouWWuSCaoLet al. HMGB1 in health and disease. Mol Aspects Med. (2014) 40:1–116. 10.1016/j.mam.2014.05.001

  • 193.

    ZhangJShaoSHanDXuYJiaoDWuJet al. High mobility group box 1 promotes the epithelial-to-mesenchymal transition in prostate cancer PC3 cells via the RAGE/NF-κB signaling pathway. Int J Oncol. (2018) 53:659–71. 10.3892/ijo.2018.4420

  • 194.

    LiHLiJZhangGDaQChenLYuSet al. HMGB1-induced p62 overexpression promotes snail-mediated epithelial-mesenchymal transition in glioblastoma cells via the degradation of GSK-3β. Theranostics. (2019) 9:1909–22. 10.7150/thno.30578

  • 195.

    FerrariSRonfaniLCalogeroSBianchiME. The mouse gene coding for high mobility group 1 protein (HMG1). J Biol Chem. (1994) 269:28803–8.

  • 196.

    SpadaFBrunetAMercierYRenardJPBianchiMEThompsonEM. High mobility group 1 (HMG1) protein in mouse preimplantation embryos. Mech Dev. (1998) 76:57–66. 10.1016/S0925-4773(98)00095-1

  • 197.

    LuoJChenJLiHYangYYunHYangSet al. LncRNA UCA1 promotes the invasion and EMT of bladder cancer cells by regulating the miR-143/HMGB1 pathway. Oncol Lett. (2017) 14:5556–62. 10.3892/ol.2017.6886

  • 198.

    WangLKangF-BWangJYangCHeD-W. Downregulation of miR-205 contributes to epithelial-mesenchymal transition and invasion in triple-negative breast cancer by targeting HMGB1-RAGE signaling pathway. Anticancer Drugs. (2019) 30:225–32. 10.1097/CAD.0000000000000705

  • 199.

    MignoneFGissiCLiuniSPesoleG. Untranslated regions of mRNAs. Genome Biol. (2002) 3:1–1010.1186/gb-2002-3-3-reviews0004

  • 200.

    KaufmanPDKobayashiRKesslerNStillmanB. The p150 and p60 subunits of chromatin assembly factor I: a molecular link between newly synthesized histones and DNA replication. Cell. (1995) 81:1105–14. 10.1016/S0092-8674(05)80015-7

  • 201.

    VerreaultAKaufmanPDKobayashiRStillmanB. Nucleosome assembly by a complex of CAF-1 and acetylated histones H3/H4. Cell. (1996) 87:95–104. 10.1016/S0092-8674(00)81326-4

  • 202.

    EndoALyTPippaRBensaddekDNicolasALamondAI. The chromatin assembly factor complex 1 (CAF1) and 5-azacytidine (5-AzaC) affect cell motility in src-transformed human epithelial cells. J Biol Chem. (2017) 292:172–84. 10.1074/jbc.M116.751024

  • 203.

    XuMJiaYLiuZDingLTianRGuHet al. Chromatin assembly factor 1, subunit A (P150) facilitates cell proliferation in human hepatocellular carcinoma. Onco Targets Ther. (2016) 9:4023–35. 10.2147/OTT.S107050

  • 204.

    XiaDYangXLiuWShenFPanJLinYet al. Over-expression of CHAF1A in epithelial ovarian cancer can promote cell proliferation and inhibit cell apoptosis. Biochem Biophys Res Commun. (2017) 486:191–7. 10.1016/j.bbrc.2017.03.026

  • 205.

    StaibanoSMascoloMManciniFPKisslingerASalvatoreGDi BenedettoMet al. Overexpression of chromatin assembly factor-1 (CAF-1) p60 is predictive of adverse behaviour of prostatic cancer. Histopathology. (2009) 54:580–9. 10.1111/j.1365-2559.2009.03266.x

  • 206.

    DuanYLiuTLiSHuangMLiXZhaoHet al. CHAF1B promotes proliferation and reduces apoptosis in 95D lung cancer cells and predicts a poor prognosis in nonsmall cell lung cancer. Oncol Rep. (2019) 41:2518–28. 10.3892/or.2019.6994

Summary

Keywords

EMT, cancer, gene regulation, epigenetics, signaling, transcription factors, chromatin

Citation

Lavin DP and Tiwari VK (2020) Unresolved Complexity in the Gene Regulatory Network Underlying EMT. Front. Oncol. 10:554. doi: 10.3389/fonc.2020.00554

Received

11 January 2020

Accepted

27 March 2020

Published

12 May 2020

Volume

10 - 2020

Edited by

Katarína Smolková, Institute of Physiology (ASCR), Czechia

Reviewed by

Eric Hervouet, Université Bourgogne Franche-Comté, France; Parames C. Sil, Bose Institute, India

Updates

Copyright

© 2020 Lavin and Tiwari.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Vijay K. Tiwari

This article was submitted to Cancer Metabolism, a section of the journal Frontiers in Oncology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Share on WeChat

Scan with WeChat to share this article

Article metrics